Vietnam is located on the eastern part of the Indochina Peninsula, bordering China to the north, Laos and Cambodia to the west, and the South China Sea to the east and south. It is the fourth-largest economy in ASEAN, with a total land area of 329,556 square kilometers. As of the end of 2023, Vietnam’s population was about 103 million. In 2023, Vietnam’s GDP grew by 5.8% year-on-year, reaching USD 435 billion, with a per capita GDP of USD 4,284, making it the fourth-largest economy in Southeast Asia and the 35th largest globally. According to the World Bank, Vietnam’s middle class and affluent class are expected to grow rapidly, accounting for 20% of the population by 2030. According to the analysis of CRI, the consistent economic development of Vietnam, the growth of the middle class, and the increasing demand for high-quality medical services are key drivers for the development of the Vietnamese medical devices industry. Additionally, increased investment in medical technology and the rapid advancement of research technologies further support the expansion of Vietnam’s medical devices market.

CRI has analyzed that the market size of Vietnam’s medical devices industry was USD 1.67 billion in 2023. Medical devices in Vietnam can be categorized into four main types: medical equipment, high-value medical consumables, low-value medical consumables, and in vitro diagnostics (IVD). Over 90% of medical devices are imported, with the United States, Japan, Singapore, Germany, and China being the main source countries. More than 30% of imports are high-end products such as MRI, CT, X-ray, and ultrasound equipment from Japan and Germany. As CRI analyzed, the medical devices of Vietnam are highly dependent on imports. Due to Vietnam’s limited basic industrial level, it mainly produces simple medical supplies, and local production cannot meet the corresponding market demand. Therefore, the Vietnamese government encourages the import of medical devices. The import tariffs on medical devices are low, without quota restrictions.

Apart from the reliance on imports, medical resources in Vietnam are also quite imbalanced. The Vietnamese medical devices market is divided into two distinct regions: the northern and southern markets. The northern region has more government departments, regulatory agencies, and national healthcare institutions, while the southern region is more concentrated with private institutions. According to CRI, high-quality medical resources in Vietnam are primarily concentrated in the capital city Hanoi and the largest city, Ho Chi Minh City. Therefore, foreign companies planning to enter the Vietnamese medical devices industry should pay special attention to these two cities.

The medical devices industry in Vietnam holds significant potential for foreign investors. According to CRI, Vietnam’s low labor costs and numerous trade agreements make it a potential investment destination for global medical devices companies. However, in high-end medical equipment and high-value medical consumables, Vietnam still faces challenges such as education, research and development of advanced technologies, and infrastructure.

CRI has forecast that Vietnam’s medical devices industry is expected to grow rapidly in the future, particularly in the low-value medical consumables segment, which has lower patent barriers. The driving forces for the medical devices market in Vietnam include the growth in domestic market demand and the increase in Vietnam’s medical devices exports. By 2033, the market size of Vietnam’s medical devices industry is expected to reach USD 3.95 billion, with a compound annual growth rate (CAGR) of 9.0% from 2024 to 2033.

Topics covered:

• Overview of Vietnam’s Medical Devices Industry
• Economic Conditions and Policies for Vietnam’s Medical Devices Industry
• Impacts of COVID-19 on the Medical Devices Industry in Vietnam
• Market Size of Vietnam’s Medical Devices Industry (2024-2033)
• Analysis of Major Medical Devices Manufacturers in Vietnam
• Key Drivers and Market Opportunities in Vietnam’s Medical Devices Industry
• What are the Main Drivers, Challenges, and Opportunities for Vietnam’s Medical Devices Industry during the Forecast Period of 2024-2033?
• Key Players in the Medical Devices Industry in Vietnam and their Competitive Advantages
• What is the Expected Revenue for Vietnam’s Medical Devices Market during the Forecast Period of 2024-2033?
• What Strategies are Major Market Players Adopting to Increase Their Market Share in the Industry?
• Which Segment of the Vietnam Medical Devices Market is Expected to Dominate by 2033?
• What are the Main Adverse Factors Facing Vietnam’s Medical Devices Industry?

Table of Contents

1. Overview of Vietnam

1.1. Geography

1.2. Demographics of Vietnam

1.3. Economic of Vietnam

1.4. Minimum Wage in Vietnam, 2015-2024

1.5. Impact of COVID-19 on Vietnam’s Medical Devices Industry

2. Development Environment of the Medical Devices Industry in Vietnam

2.1. History of the Medical Devices Industry in Vietnam

2.2. Categories of Medical Devices in Vietnam

2.3. Policies for the Medical Devices Industry in Vietnam

3. Supply and Demand of the Medical Devices Industry in Vietnam

3.1. Supply of the Medical Devices Industry in Vietnam

3.1.1. Production Capacity

3.1.2. Production Volume

3.2. Demand of the Medical Devices Industry in Vietnam

3.2.1. Demand Volume

3.2.2. Market Size

4. Import and Export of the Medical Devices Industry in Vietnam

4.1. Import of the Medical Devices Industry in Vietnam

4.1.1. Import Volume and Value of Medical Devices in Vietnam

4.1.2. Main Suppliers of Medical Devices Imports in Vietnam

4.2. Export of the Medical Devices Industry in Vietnam

4.2.1. Export Volume and Value of Medical Devices in Vietnam

4.2.2. Main Destinations of Medical Devices Exports in Vietnam

5. Market Competition of Vietnam’s Medical Devices Industry

5.1. Barriers to Entry in Vietnam’s Medical Devices Industry

5.1.1. Brand Barriers

5.1.2. Quality Barriers

5.1.3. Capital Barriers

5.2. Competitive Structure of Vietnam’s Medical Devices Industry

5.2.1. Bargaining Power of Medical Devices Suppliers

5.2.2. Bargaining Power of Consumers

5.2.3. Competitive Landscape of Vietnam’s Medical Devices Industry

5.2.4. Potential Entrants in the Medical Devices Industry

5.2.5. Substitutes for Medical Devices Products

6. Analysis of Major Medical Devices Brands in Vietnam

6.1. Medtronic

6.1.1. History of Medtronic

6.1.2. Main Products of Medtronic

6.1.3. Operating Model of Medtronic

6.2. Johnson & Johnson

6.2.1. History of Johnson & Johnson

6.2.2. Main Products of Johnson & Johnson

6.2.3. Operating Model of Johnson & Johnson

6.3. Becton Dickinson

6.3.1. History of Becton Dickinson

6.3.2. Main Products of Becton Dickinson

6.3.3. Operating Model of Becton Dickinson

6.4. Siemens Healthineers

6.4.1. History of Siemens Healthineers

6.4.2. Main Products of Siemens Healthineers

6.4.3. Operating Model of Siemens Healthineers

6.5. Boston Scientific

6.5.1. History of Boston Scientific

6.5.2. Main Products of Boston Scientific

6.5.3. Operating Model of Boston Scientific

6.6. Stryker Corporation

6.6.1. History of Stryker Corporation

6.6.2. Main Products of Stryker Corporation

6.6.3. Operating Model of Stryker Corporation

6.7. Danaher Corporation

6.7.1. History of Danaher Corporation

6.7.2. Main Products of Danaher Corporation

6.7.3. Operating Model of Danaher Corporation

6.8. Philips Healthcare

6.8.1. History of Philips Healthcare

6.8.2. Main Products of Philips Healthcare

6.8.3. Operating Model of Philips Healthcare

6.9. USM Healthcare Medical Devices Factory JSC

6.9.1. History of USM Healthcare Medical Devices Factory JSC

6.9.2. Main Products of USM Healthcare Medical Devices Factory JSC

6.9.3. Operating Model of USM Healthcare Medical Devices Factory JSC

6.10. VIMEDTEC., JSC

6.10.1. History of VIMEDTEC., JSC

6.10.2. Main Products of VIMEDTEC., JSC

6.10.3. Operating Model of VIMEDTEC., JSC

7. Outlook for Vietnam’s Medical Devices Industry (2024-2033)

7.1. Development Factors of Vietnam’s Medical Devices Industry

7.1.1. Drivers and Opportunities of the Medical Devices Industry in Vietnam

7.1.2. Threats and Challenges facing the Medical Devices Industry in Vietnam

7.2. Market Supply Forecast for the Medical Devices Industry in Vietnam

7.3. Market Demand Forecast for the Medical Devices Industry in Vietnam

7.4. Import and Export Forecast for the Medical Devices Industry in Vietnam

List of Charts

Chart Population of Vietnam, 2009-2023

Chart GDP Per Capita in Vietnam, 2014-2023

Chart Related Policies Issued by Vietnam Government for Medical Devices Industry, 2019-2023

Chart Production of Medical Devices in Vietnam, 2019-2023

Chart Medical Devices Domestic Consumption in Vietnam, 2019-2023

Chart Import Volume of Medical Devices in Vietnam, 2019-2023

Chart Import Value of Medical Devices in Vietnam, 2019-2023

Chart Main Suppliers and their Import Values of Medical Devices Imports in Vietnam, 2019-2023

Chart Export Volume of Medical Devices and Final Products in Vietnam, 2019-2023

Chart Export Value of Medical Devices and Final Products in Vietnam, 2019-2023

Chart Main Export Destinations and their Export Values for Medical Devices from Vietnam, 2019-2023

Chart Production Forecast for the Vietnamese Medical Devices Industry, 2024-2033

Chart Domestic Market Size Forecast for the Vietnamese Medical Devices Industry, 2024-2033

Chart Import Forecast for the Vietnamese Medical Devices Industry, 2024-2033

Chart Export Forecast for the Vietnamese Medical Devices Industry, 2024-2033

The post Vietnam Medical Devices Industry Research Report 2024-2033 first appeared on CRI Report.

Singapore is located at the southern tip of the Malay Peninsula, at the entrance of the Straits of Malacca. It is bordered to the north by Malaysia across the Johor Strait and to the south by Indonesia across the Singapore Strait. Comprising Singapore Island and 63 other islands, the country covers a total land area of 733.2 square kilometers. Singapore is not only the only developed country in Southeast Asia but also the fourth-largest international financial center after New York, London, and Hong Kong. Over the past decade, Singapore’s nominal GDP has grown from US$ 314.86 billion in 2014 to US$ 501.31 billion in 2023, with a per capita GDP exceeding $80,000 in 2023.

According to the Population in Brief 2023 released by Singapore’s Population and Talent Division, as of June 2023, Singapore’s total population was approximately 5.92 million, with citizens aged 65 and above accounting for 19.1%. Additionally, the preliminary estimate for Singapore’s total fertility rate in 2023 was 0.97, falling below 1 for the first time, indicating an accelerating trend of population aging.

The medical devices market in Singapore reached $3.23 billion in 2023. According to CRI, the market size of Singapore’s medical devices has shown continuous growth over the past few years. Ranked by the World Health Organization, Singapore boasts the sixth most efficient healthcare system globally and the fourth-best healthcare infrastructure, attracting patients from neighboring Southeast Asian countries and other parts of the world. The aging population and the increasing burden of chronic diseases, the rising demand for high-quality healthcare services, and a thriving medical tourism industry have been key drivers of the rapid development of Singapore’s medical devices industry in recent years. Singapore currently has 19 public hospitals, which are the largest customers in the medical devices industry, accounting for nearly 70% of the total demand, with private hospitals also being major consumers of medical devices.

Foreign enterprises dominate over 80% of the medical devices market in Singapore, primarily producing and supplying high-end medical equipment. Major companies include Abbott, Alcon, Becton Dickinson, Medtronic, and Siemens Healthineers. CRI has analyzed that while there are a few local companies in Singapore’s medical devices industry, they are mostly small enterprises mainly supplying medical consumables.

With the aging population trend and the increasing number of chronic disease patients, the demand for medical devices in Singapore will continue to grow. CRI expects the medical devices industry in Singapore to be further driven by technological innovation and digital transformation in the coming years. Digital healthcare solutions such as telemedicine, medical data analytics, and smart medical devices will gradually become widespread, providing new growth opportunities for Singapore’s medical devices industry. However, the development of the industry also faces challenges, including increasingly stringent regulatory and compliance requirements, necessitating strengthened quality management systems by companies. Additionally, market competition is becoming increasingly intense.

CRI forecasts that in the coming years, driven by factors such as population growth and technological advancements, Singapore’s medical devices industry has significant development potential. It is projected that the market size of Singapore’s medical devices industry will reach US$ 7.11 billion by 2033, with a compound annual growth rate (CAGR) of 8.2% from 2024 to 2033.

Topics covered:

• Overview of Singapore’s Medical Devices Industry
• Economic Conditions and Policies for Singapore’s Medical Devices Industry
• How Foreign Investment Enters Singapore’s Medical Devices Market
• Market Size of Singapore’s Medical Devices Industry (2024-2033)
• Analysis of Major Medical Devices Manufacturers in Singapore
• Key Drives and Market Opportunities for the Medical Devices Industry in Singapore
• What are the Major Drivers, Challenges, and Opportunities for the Medical Devices Industry in Singapore during the Forecast Period 2024-2033?
• Who are the Main Players in Singapore’s Medical Devices Market and What are their Competitive Advantages?
• What is the Expected Revenue of Singapore’s Medical Devices Market during the Forecast Period 2024-2033?
• What Strategies have the Major Market Players Adopted to Increase their Market Share in the Industry?
• Which Segment of Singapore’s Medical Devices Market is Expected to Dominate the Market by 2032?
• What are the Main Adverse Factors Facing the Singapore Medical Devices Industry?

Table of Contents

1. Overview of Singapore

1.1 Geography

1.2 Demographics of Singapore

1.3 Economic of Singapore

1.4. Minimum Wage in Singapore, 2015-2024

1.5. Impact of COVID-19 on Singapore’s Medical Devices Industry

2. Development Environment of the Medical Devices Industry in Singapore

2.1. History of the Medical Devices Industry in Singapore

2.2. Categories of Medical Devices in Singapore

2.3. Policies for the Medical Devices Industry in Singapore

3. Supply and Demand of the Medical Devices Industry in Singapore

3.1. Supply of the Medical Devices Industry in Singapore

3.1.1. Production Capacity

3.1.2. Production Volume

3.2. Demand of the Medical Devices Industry in Singapore

3.2.1. Demand Volume

3.2.2. Market Size

4. Import and Export of the Medical Devices Industry in Singapore

4.1. Import of the Medical Devices Industry in Singapore

4.1.1. Import Volume and Value of Medical Devices in Singapore

4.1.2. Main Suppliers of Medical Devices Imports in Singapore

4.2. Export of the Medical Devices Industry in Singapore

4.2.1. Export Volume and Value of Medical Devices in Singapore

4.2.2. Main Destinations of Medical Devices Exports in Singapore

5. Market Competition of Singapore’s Medical Devices Industry

5.1. Barriers to Entry in Singapore’s Medical Devices Industry

5.1.1. Brand Barriers

5.1.2. Quality Barriers

5.1.3. Capital Barriers

5.2. Competitive Structure of Singapore’s Medical Devices Industry

5.2.1. Bargaining Power of Medical Devices Suppliers

5.2.2. Bargaining Power of Consumers

5.2.3. Competitive Landscape of Singapore’s Medical Devices Industry

5.2.4. Potential Entrants in the Medical Devices Industry

5.2.5. Substitutes for Medical Devices Products

6. Analysis of Major Medical Devices Brands in Singapore

6.1. Abbott

6.1.1. History of Abbott

6.1.2. Main Products of Abbott

6.1.3. Operating Model of Abbott

6.2. Alcon

6.2.1. History of Alcon

6.2.2. Main Products of Alcon

6.2.3. Operating Model of Alcon

6.3. Becton Dickinson

6.3.1. History of Becton Dickinson

6.3.2. Main Products of Becton Dickinson

6.3.3. Operating Model of Becton Dickinson

6.4. Medtronic

6.4.1. History of Medtronic

6.4.2. Main Products of Medtronic

6.4.3. Operating Model of Medtronic

6.5. Biosensors International

6.5.1. History of Biosensors International

6.5.2. Main Products of Biosensors International

6.5.3. Operating Model of Biosensors International

6.6. Nipro Corp

6.6.1. History of Nipro Corp

6.6.2. Main Products of Nipro Corp

6.6.3. Operating Model of Nipro Corp

6.7. B. Braun Singapore Pte Ltd

6.7.1. History of B. Braun Singapore Pte Ltd

6.7.2. Main Products of B. Braun Singapore Pte Ltd

6.7.3. Operating Model of B. Braun Singapore Pte Ltd

6.8. Danaher Corporation

6.8.1. History of Danaher Corporation

6.8.2. Main Products of Danaher Corporation

6.8.3. Operating Model of Danaher Corporation

6.9. Siemens Healthineers

6.9.1. History of Siemens Healthineers

6.9.2. Main Products of Siemens Healthineers

6.9.3. Operating Model of Siemens Healthineers

6.10. Boston Scientific

6.10.1. History of Boston Scientific

6.10.2. Main Products of Boston Scientific

6.10.3. Operating Model of Boston Scientific

7. Outlook for Singapore’s Medical Devices Industry (2024-2033)

7.1. Development Factors of Singapore’s Medical Devices Industry

7.1.1. Drivers and Opportunities of the Medical Devices Industry in Singapore

7.1.2. Threats and Challenges facing the Medical Devices Industry in Singapore

7.2. Market Supply Forecast for the Medical Devices Industry in Singapore

7.3. Market Demand Forecast for the Medical Devices Industry in Singapore

7.4. Import and Export Forecast for the Medical Devices Industry in Singapore

List of Charts

Chart Population of Singapore, 2009-2023

Chart GDP Per Capita in Singapore, 2014-2023

Chart Related Policies Issued by Singapore Government for Medical Devices Industry, 2019-2023

Chart Production of Medical Devices in Singapore, 2019-2023

Chart Medical Devices Domestic Consumption in Singapore, 2019-2023

Chart Import Volume of Medical Devices in Singapore, 2019-2023

Chart Import Value of Medical Devices in Singapore, 2019-2023

Chart Main Suppliers and their Import Values of Medical Devices Imports in Singapore, 2019-2023

Chart Export Volume of Medical Devices and Final Products in Singapore, 2019-2023

Chart Export Value of Medical Devices and Final Products in Singapore, 2019-2023

Chart Main Export Destinations and their Export Values for Medical Devices from Singapore, 2019-2023

Chart Production Forecast for the Singapore Medical Devices Industry, 2024-2033

Chart Domestic Market Size Forecast for the Singapore Medical Devices Industry, 2024-2033

Chart Import Forecast for the Singapore Medical Devices Industry, 2024-2033

Chart Export Forecast for the Singapore Medical Devices Industry, 2024-2033

The post Singapore Medical Devices Industry Research Report 2024-2033 first appeared on CRI Report.

Indonesia, located in Southeast Asia, is the world’s largest archipelago, spanning both Asia and Oceania, earning it the nickname “the country of a thousand islands.” With a population exceeding 280 million, it is the fourth most populous country in the world and boasts the largest consumer market in Southeast Asia. According to CRI, Indonesia’s economy has been growing steadily over the past decade, with a compound annual growth rate (CAGR) of 3.9% for per capita GDP from 2014 to 2023. In 2023, Indonesia’s per capita GDP reached US$4,914, up 2.7% year-on-year. The country’s actual GDP, calculated at constant 2010 market prices, was $1.41 trillion in 2023, a 5.05% increase from the previous year, although this growth rate was 0.3% lower than in 2022. Despite the slight slowdown, Indonesia’s GDP growth rate remains significantly higher than the global average of 2.6%.

The Indonesian medical devices market reached US$4.38 billion in 2023. According to CRI, this growth is primarily due to the expansion of both public and private hospitals and the implementation of Indonesia’s public health insurance system, BPJS-Kesehatan (Jaminan Kesehatan Nasional, or JKN), in 2014. As of July 2023, the system covered 258.2 million people, approximately 90.34% of Indonesia’s total population. These factors have increased demand for advanced medical equipment and supplies, driving the continuous growth of the Indonesian medical devices market.

Indonesia is heavily reliant on imports for its medical devices, with estimates suggesting that over 70% of medical devices are imported, and this figure was as high as 88% before 2022. To boost the local medical devices industry, Indonesia introduced localization content requirements in June 2021, prohibiting the import of 5,400 medical devices across 79 categories for public procurement systems unless they meet a 40% local content requirement. Despite government efforts to encourage local production and adjust import tariffs, Indonesia still relies heavily on imports for advanced medical equipment based on the analysis of CRI. Currently, Indonesia mainly produces and exports lower-value, less technologically advanced medical consumables such as surgical gloves and bandages.

Indonesia has been encouraging foreign investment in its medical devices sector. The government has stated that Indonesia will prioritize using domestically produced medical supplies and will not import medical equipment that can be produced locally, thereby encouraging foreign companies to establish manufacturing plants in Indonesia. Additionally, Presidential Regulation No. 10 of 2021 on Investment List, issued in February 2021, promotes foreign investment by allowing companies to have 100% foreign ownership of imported and regulatory-approved medical devices, giving foreign companies complete legal control over their subsidiaries in Indonesia.

With population growth, economic development, and the introduction of investment-friendly policies, CRI projects that the Indonesian medical devices market will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2033, reaching US$10.47 billion by 2033.

Topics covered:

• Overview of Indonesia’s Medical Devices Industry
• Economic Conditions and Policies for Indonesia’s Medical Devices Industry
• Impacts of COVID-19 on the Medical Devices Industry in Indonesia
• Market Size of Indonesia’s Medical Devices Industry (2024-2033)
• Analysis of Major Medical Devices Manufacturers in Indonesia
• Key Drivers and Market Opportunities in Indonesia’s Medical Devices Industry
• What are the Main Drivers, Challenges, and Opportunities for Indonesia’s Medical Devices Industry during the Forecast Period of 2024-2033?
• Key Players in the Medical Devices Industry in Indonesia and their Competitive Advantages
• What is the Expected Revenue for Indonesia’s Medical Devices Market during the Forecast Period of 2024-2033?
• What Strategies are Major Market Players Adopting to Increase Their Market Share in the Industry?
• Which Segment of the Indonesia Medical Devices Market is Expected to Dominate by 2033?
• What are the Main Adverse Factors Facing Indonesia’s Medical Devices Industry?

Table of Contents

1. Overview of Indonesia

1.1 Geography

1.2 Demographics of Indonesia

1.3 Economic of Indonesia

1.4. Minimum Wage in Indonesia, 2015-2024

1.5. Impact of COVID-19 on Indonesia’s Medical Devices Industry

2. Development Environment of the Medical Devices Industry in Indonesia

2.1. History of the Medical Devices Industry in Indonesia

2.2. Categories of Medical Devices in Indonesia

2.3. Policies for the Medical Devices Industry in Indonesia

3. Supply and Demand of the Medical Devices Industry in Indonesia

3.1. Supply of the Medical Devices Industry in Indonesia

3.1.1. Production Capacity

3.1.2. Production Volume

3.2. Demand of the Medical Devices Industry in Indonesia

3.2.1. Demand Volume

3.2.2. Market Size

4. Import and Export of the Medical Devices Industry in Indonesia

4.1. Import of the Medical Devices Industry in Indonesia

4.1.1. Import Volume and Value of Medical Devices in Indonesia

4.1.2. Main Suppliers of Medical Devices Imports in Indonesia

4.2. Export of the Medical Devices Industry in Indonesia

4.2.1. Export Volume and Value of Medical Devices in Indonesia

4.2.2. Main Destinations of Medical Devices Exports in Indonesia

5. Market Competition of Indonesia’s Medical Devices Industry

5.1. Barriers to Entry in Indonesia’s Medical Devices Industry

5.1.1. Brand Barriers

5.1.2. Quality Barriers

5.1.3. Capital Barriers

5.2. Competitive Structure of Indonesia’s Medical Devices Industry

5.2.1. Bargaining Power of Medical Devices Suppliers

5.2.2. Bargaining Power of Consumers

5.2.3. Competitive Landscape of Indonesia’s Medical Devices Industry

5.2.4. Potential Entrants in the Medical Devices Industry

5.2.5. Substitutes for Medical Devices Products

6. Analysis of Major Medical Devices Brands in Indonesia

6.1. Medtronic

6.1.1. History of Medtronic

6.1.2. Main Products of Medtronic

6.1.3. Operating Model of Medtronic

6.2. Becton Dickinson

6.2.1. History of Becton Dickinson

6.2.2. Main Products of Becton Dickinson

6.2.3. Operating Model of Becton Dickinson

6.3. Johnson & Johnson

6.3.1. History of Johnson & Johnson

6.3.2. Main Products of Johnson & Johnson

6.3.3. Operating Model of Johnson & Johnson

6.4. Siemens Healthineers

6.4.1. History of Siemens Healthineers

6.4.2. Main Products of Siemens Healthineers

6.4.3. Operating Model of Siemens Healthineers

6.5. Philips Healthcare

6.5.1. History of Philips Healthcare

6.5.2. Main Products of Philips Healthcare

6.5.3. Operating Model of Philips Healthcare

6.6. GE Healthcare

6.6.1. History of GE Healthcare

6.6.2. Main Products of GE Healthcare

6.6.3. Operating Model of GE Healthcare

6.7. Boston Scientific

6.7.1. History of Boston Scientific

6.7.2. Main Products of Boston Scientific

6.7.3. Operating Model of Boston Scientific

6.8. Danaher Corporation

6.8.1. History of Danaher Corporation

6.8.2. Main Products of Danaher Corporation

6.8.3. Operating Model of Danaher Corporation

6.9. Stryker

6.9.1. History of Stryker

6.9.2. Main Products of Stryker

6.9.3. Operating Model of Stryker

6.10. Mindray Indonesia

6.10.1. History of Mindray Indonesia

6.10.2. Main Products of Mindray Indonesia

6.10.3. Operating Model of Mindray Indonesia

7. Outlook for Indonesia’s Medical Devices Industry (2024-2033)

7.1. Development Factors of Indonesia’s Medical Devices Industry

7.1.1. Drivers and Opportunities of the Medical Devices Industry in Indonesia

7.1.2. Threats and Challenges facing the Medical Devices Industry in Indonesia

7.2. Market Supply Forecast for the Medical Devices Industry in Indonesia

7.3. Market Demand Forecast for the Medical Devices Industry in Indonesia

7.4. Import and Export Forecast for the Medical Devices Industry in Indonesia

List of Charts

Chart Population of Indonesia, 2009-2023

Chart GDP Per Capita in Indonesia, 2014-2023

Chart Related Policies Issued by Indonesia Government for Medical Devices Industry, 2019-2023

Chart Production of Medical Devices in Indonesia, 2019-2023

Chart Medical Devices Domestic Consumption in Indonesia, 2019-2023

Chart Import Volume of Medical Devices in Indonesia, 2019-2023

Chart Import Value of Medical Devices in Indonesia, 2019-2023

Chart Main Suppliers and their Import Values of Medical Devices Imports in Indonesia, 2019-2023

Chart Export Volume of Medical Devices and Final Products in Indonesia, 2019-2023

Chart Export Value of Medical Devices and Final Products in Indonesia, 2019-2023

Chart Main Export Destinations and their Export Values for Medical Devices from Indonesia, 2019-2023

Chart Production Forecast for the Indonesia Medical Devices Industry, 2024-2033

Chart Domestic Market Size Forecast for the Indonesia Medical Devices Industry, 2024-2033

Chart Import Forecast for the Indonesia Medical Devices Industry, 2024-2033

Chart Export Forecast for the Indonesia Medical Devices Industry, 2024-2033

The post Indonesia Medical Devices Industry Research Report 2024-2033 first appeared on CRI Report.

The global rare disease genetic testing market was valued at $4.11 billion in 2022 and is anticipated to reach $16.69 billion by 2033, witnessing a CAGR of 13.69% during the forecast period 2023-2033. Cutting-edge technologies, such as whole-genome sequencing (WGS) and whole-exome sequencing (WES), involve the analysis of an individual’s complete genetic code (genome) or specific protein-coding regions (exome), respectively. These methods help identify genetic variations, mutations, or abnormalities responsible for rare diseases.

Market Introduction

Before the advent of NGS (which includes WGS and WES), physicians relied on the Sanger sequencing-based tests, which could detect rare diseases but were extremely time-consuming. Additionally, till all the tests were completed, physicians had to rely on a general diagnostic odyssey or general diagnosis until definitive results were available. This delayed the treatment process. As per BIS research, the global rare disease genetic testing market includes panels and tests that can be used for more rare disease genetic testing. These are predominantly polymerase chain reaction (PCR) and next-generation sequencing (NGS) based tests, panels, and assays. The most common rare disease genetic testing panels include gastroenterology, endocrine and metabolism, and neurology disease, among others.

Industrial Impact

The global rare disease genetic testing market has witnessed significant growth, attributed to the increasing demand for early detection of rare diseases. The increasing prevalence of rare diseases has played a critical role in market growth. Furthermore, growing recognition and emphasis on early detection and prevention of rare diseases in pediatric populations around the world are also expected to influence market growth.

Rare disease genetic testing has immense potential to deliver next-level healthcare solutions. For instance, in January 2023, BGI Genomics, in collaboration with the National Centre for Cardiovascular Diseases, Fuwai Hospital, and the State Key Laboratory of Cardiovascular Diseases, developed the “CardioGen automated interpretation system,” which serves as the genotype and phenotype database of monogenic cardiovascular disease. Other factors also impact the market growth, including increased patient demand and low turnaround time of these tests.

Market Segmentation:

Segmentation 1: by Disease Type
•    Gastroenterology Disease
•    Endocrine and Metabolism Disease
•    Cardiovascular Disease
•    Neurology Disease
•    Hematology and Oncology Disease
•    Dermatology Disease
•    Other Diseases

Endocrine and Metabolism Disease Segment to Dominate the Global Rare Disease Genetic Testing Market (by Disease Type)

Based on disease type, the rare disease genetic testing market is led by endocrine and metabolism, which held a 21.88% share in 2022. The burden of endocrine and metabolism diseases often has a high prevalence in the general population, making their diagnosis and management particularly challenging. Their diagnosis addresses genetic testing such as NGS. Further, it also includes biomarker analysis, newborn screening, and molecular diagnostic techniques.

Segmentation 2: Offering
•    Products
•    Services

Services Segment to Dominate the Global Rare Disease Genetic Testing Market (by Offering)

Based on offerings, the rare disease genetic testing market is led by services, which held an 81.58% share in 2022. Services are specifically tailored to meet the distinct requirements of individuals affected by rare diseases, healthcare professionals, and researchers engaged in this field. The availability of these services complements the use of diagnostic products and facilitates comprehensive and personalized rare disease genetic testing.

Segmentation 3: by Specialty Type
•    Molecular Genetic Tests
•    Chromosomal Genetic Tests
•    Biochemical Genetic Tests

Molecular Genetic Tests Occupying the Largest Share in the Market (by Specialty Type)

Based on specialty type, the rare disease genetic testing market is led by molecular genetic tests, which held a 58.89% share in 2022. The key reason for the increasing popularity of molecular genetic testing is that it provides crucial information for genetic counseling and family planning for individuals and families affected by rare diseases. By identifying specific genetic mutations, families can gain insights into the likelihood of disease inheritance and assess the risk of passing on the condition to future generations. This type of testing is utilized to identify genetic disorders in newborns, allowing for prompt intervention and treatment initiation.

Segmentation 4: by Sample Type
•    DNA Sample
•    Buccal Swab Sample
•    Blood Sample
•    Saliva Sample
•    Others

Blood Sample to Witness the Highest Growth Between 2023 and 2033

Based on sample type, the rare disease genetic testing market is led by blood samples, and it held a 33.99% share in 2022. Blood samples undergo processing to isolate different components, including white blood cells, serum, or plasma. These isolated components are then subjected to further analysis to detect genetic abnormalities, identify biochemical markers, or explore other diagnostic indicators. Genetic testing methods such as PCR, DNA sequencing, and microarrays can be employed on blood samples to identify specific genetic mutations that are associated with rare diseases.

Segmentation 5: by Trait Type
•    Inherited Trait
•    Acquired Trait

Inherited Trait to Witness the Highest Growth between 2023 and 2033

Based on trait type, the rare disease genetic testing market is led by inherited traits, which held an 82.59% share in 2022. Inherited traits are characteristics or conditions that are passed down from parents to their offspring through genetic material, i.e., DNA. These traits result from variations or mutations in the genes and can increase the risk of developing certain rare diseases.

Segmentation 6: by Technology
•    Sanger Sequencing
•    PCR
•    NGS
•    Microarrays
•    Others (Targeted Cytogenetics, Karyotyping, and FISH)

NGS to Dominate the Global Rare Disease Genetic Testing Market (by Technology)

Based on technology, the rare disease genetic testing market is led by next-generation sequencing (NGS), and it held a 43.80% share in 2022. NGS technology provides higher sensitivity and specificity in detecting genetic variants, including single-nucleotide variants (SNVs), insertions, deletions, and structural rearrangements. This technology also extends its applications to non-invasive prenatal testing, including the detection of fetal chromosomal abnormalities associated with certain rare genetic conditions.

Segmentation 7: by Age Group
•    Prenatal
•    Neonate and Infant
•    Children and Adolescent
•    Adult

Prenatal to Witness the Highest Growth between 2023 and 2033

Based on age group, the rare disease genetic testing market is led by the prenatal age group, which held a 39.68% share in 2022. Prenatal testing and diagnostics play a crucial role in identifying potential rare diseases and congenital abnormalities in the fetus. Prenatal testing methods such as chorionic villus sampling (CVS) and amniocentesis are employed to detect genetic disorders or developmental issues.

Segmentation 8: by End User
•    Hospital
•    Diagnostics Laboratories
•    Other End Users

Hospitals to Dominate the Global Rare Disease Genetic Testing Market (by End User)

Based on end users, the rare disease genetic testing market is led by hospitals, which recorded a 53.12% share in 2022. Hospitals are at the forefront of adopting syndromic testing panels into routine healthcare procedures. Hospitals, particularly in leading regions such as North America and Europe, and also to a certain extent in Asia-Pacific, have incorporated syndromic testing panels and assays to provide superior care to patients.

Segmentation 9: by Region
•    North America – U.S., Canada
•    Europe – Germany, U.K., France, Italy, Russia, Spain, and Rest-of-Europe
•    Asia-Pacific – Japan, India, China, South Korea, Australia, Singapore, and Rest-of-Asia-Pacific
•    Latin America – Brazil, Mexico, and Rest-of-Latin America
•    Rest-of-the-World

Regions such as North America and Europe have technologically advanced industries and allocate considerable budgets to research and development (R&D) activities. Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.

Recent Developments in the Rare Disease Genetic Testing Market

•    In April 2023, Agilent Technologies, Inc. and Theragen Bio collaborated in South Korea to advance bioinformatic solutions for cancer genomic profiling.
•    In April 2023, 3 billion receives accreditation from the  California Department of Public Health (CDPH) as a clinical laboratory. With the CDPH accreditation, hospitals throughout California will now be able to utilize 3 billion’s genetic tests for diagnostic purposes and can claim insurance for the tests.
•    In February 2023, Akili Labs and BGI Genomics established the first commercial clinical sequencing facility in Africa.
•    In January 2023, Premier Research and CENTOGENE formed a strategic partnership to hasten and reduce the risk of clinical development for rare diseases.
•    In February 2023, Illumina delivers the first NovaSeq X Plus sequencer and workflow insights on Illumina Complete Long Reads unveiled at Advances in Genome Biology and Technology (AGBT).
•    In March 2023, Invitae Announces Partnership with Epic to Streamline Genetic Testing. Through Aura, Epic’s specialty diagnostics suite, Invitae will streamline interactions with provider organizations in the Epic community, making test result information available in providers’ usual workflows so that it’s easier to use genetic insights to inform treatment decisions.

Demand – Drivers, Challenges, and Opportunities

Market Demand Drivers:

Rapid Technological Advancements in Rare Disease Diagnosis: Technological advancements, such as next-generation sequencing (NGS), targeted gene panels, and artificial intelligence (AI)-based algorithms, have significantly improved diagnostic accuracy for rare diseases. NGS enables comprehensive genomic analysis, allowing for the identification of disease-causing genetic mutations with higher precision. By identifying the underlying genetic mechanisms and individualizing treatment plans, technological advancements are improving patient outcomes, patient satisfaction, and overall market growth. These advancements have also led to the emergence of new areas of rare disease genetic testing, which have opened up new avenues for research and drug discovery.

Rising Prevalence of Genetic Disorders and Congenital Disorders: The rising prevalence of genetic disorders and congenital disorders has a significant impact on the growth of the global rare disease genetic testing market. Increased demand for diagnostic services, expansion of screening programs, focus on personalized medicine, research and development initiatives, supportive regulatory environment, and patient advocacy all contribute to the expanding market. Furthermore, the rising prevalence led to an expansion of screening programs. Governments and healthcare organizations are implementing newborn screening programs and prenatal genetic testing initiatives to identify these disorders early.

Growing Recognition and Emphasis on Early Detection and Prevention of Rare Diseases in Paediatric Populations: Increased consumer demand for early detection and prevention, coupled with a focus on personalized medicine and precision healthcare, is expected to fuel the growth of the global rare disease market. Awareness and education, patient empowerment, expanded screening programs, preventive healthcare strategies, supportive policies, and insurance coverage are all contributing to the expansion of diagnostic services and driving market demand for rare disease genetic testing.

Market Challenges:

Lack of Consolidation of Information Leading to Difficulty in Diagnosis: The lack of consolidation of information and the resulting difficulty in diagnosis poses significant challenges for the global rare disease genetic testing market. Rare diseases often have limited available information, fragmented research findings, and scattered expertise. The vast number of rare diseases, each with its unique set of symptoms and genetic variations, makes it challenging to consolidate comprehensive knowledge and expertise in a centralized manner.

Significant Capital Requirement for Research and Development Hindering Global Expansion Efforts: The significant capital requirement for research and development (R&D) poses a notable challenge for the global rare disease genetic testing market. Research and development in the field of rare diseases often involve extensive genetic studies, clinical trials, and the development of innovative diagnostic tools and therapies. These activities require substantial financial investment, as they involve specialized expertise, laboratory infrastructure, regulatory compliance, and patient recruitment. The high costs associated with R&D act as a barrier, particularly for smaller companies and research institutions with limited resources, hindering their ability to undertake comprehensive research and development efforts. Rare diseases, by definition, affect a small patient population. Hence, the limited commercial market potential for treatments and diagnostics creates challenges in attracting sufficient private investment.

Market Opportunities:

Whole-Genome Sequencing Putting an End to the Rare Disease Diagnostic Odysseys: Whole-genome sequencing (WGS) has the potential to put an end to rare disease genetic testing odysseys and presents significant opportunities for the global rare disease genetic testing market. This technology enables a comprehensive analysis of an individual’s entire genome, providing a comprehensive view of the genetic variations and mutations. This approach allows for the detection of both common and rare genetic variants, including those associated with rare diseases.

AI-Based Diagnostic Tools Diagnosing Rare Diseases by Identifying Potential Diagnoses: AI-based diagnostic tools that utilize machine learning and artificial intelligence algorithms present significant opportunities for the global rare disease market by improving the diagnosis of rare diseases. Artificial intelligence (AI) and machine learning algorithms are revolutionizing rare disease genetic testing by analyzing large datasets, identifying patterns, and making accurate predictions. For instance, in July 2021, Sema4, the parent organization of GeneDx, successfully concluded a transaction with CM Life Sciences, marking its debut as a publicly traded company. The company now operates as an AI-driven genomics and clinical data platform company.

Transitioning toward Increased Genetics Coverage in Reimbursement Policies: Transitioning toward increased genetics coverage in reimbursement policies presents a valuable opportunity for the global rare disease genetic testing market. It improves access to genetic testing, encourages early diagnosis and intervention, supports research and development efforts, stimulates innovation, reduces financial burdens for patients, and aligns with the principles of personalized medicine. These factors collectively contribute to improved diagnostic rates and advancements in rare disease management.

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The global rare disease genetic testing market has been extensively segmented on the basis of various categories, such as disease type, specialty type, sample type, end-user, and region. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Partnerships, collaborations, product launches, and upgrades accounted for the maximum number of key developments, i.e., nearly 86.2% of the total developments in the global rare disease genetic testing market were between January 2021 and June 2023.

Competitive Strategy: The global rare disease genetic testing market has numerous established players paving their way into providing tests, panels, and assays in the market. Key players in the global rare disease genetic testing market analyzed and profiled in the study involve established players offering various disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Key Companies Profiled:

•    23andMe Holding Co.
•    3billion, Inc.
•    Agilent Technologies, Inc.
•    Konica Minolta (Ambry Genetics, Inc.)
•    BGI Group
•    CENTOGENE N.V.
•    Eurofins Scientific SE
•    GeneDx, Holdings Corp.
•    Azenta U.S., Inc. (GENEWIZ, Inc.)
•    Illumina, Inc.
•    Invitae Corporation
•    Laboratory Corporation of America Holdings
•    Medgenome
•    Myriad Genetics, Inc.
•    OPKO Health, Inc.
•    PerkinElmer, Inc.
•    Exact Sciences Corporation (Prevention Genetics)
•    QIAGEN N.V.
•    Quest Diagnostics Incorporated
•    Strand Life Science Pvt Ltd.

The post Rare Disease Genetic Testing Market – A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis – Analysis and Forecast, 2023-2033 first appeared on CRI Report.

The India emerging infectious disease diagnostics market is projected to experience substantial growth over the forecast period 2023-2033. Moreover, the market value for 2022 was estimated to be $339.1 million and is expected to reach $982.7 million by 2033, showcasing a CAGR of 10.29% during the forecast period.

Market Lifecycle Stage

The India emerging infectious disease diagnostics market is in an emerging phase. Recent years have seen improvements and innovations in diagnostic methods, particularly with the advent of next-generation sequencing and the growing demand for rapid testing (such as in the case of the COVID-19 pandemic). New technologies and devices that offer faster, more efficient, or more cost-effective extraction could rejuvenate the market and push it back toward a growth phase.

Industry Impact

The India emerging infectious disease diagnostics market has proven to be a cornerstone in the evolution of modern biotechnology, clinical diagnostics, and research of different pathogens. Infectious disease diagnostics have a significant impact on various aspects of healthcare and public health. Here are some key impacts:

Accurate and Timely Diagnosis: Infectious disease diagnostics enable healthcare providers to accurately identify the causative agents of infections, leading to timely and appropriate treatment. Early diagnosis helps improve patient outcomes, reduce morbidity and mortality rates, and prevent the spread of infectious diseases.

Effective Patient Management: Diagnostic tests provide critical information for healthcare providers to guide patient management strategies. These tests help determine the most effective treatment options, including the selection of appropriate antimicrobial therapies and the implementation of infection control measures. This leads to better patient care and improved healthcare outcomes.

Public Health Surveillance and Outbreak Control: Infectious disease diagnostics play a crucial role in public health surveillance. By identifying and monitoring infectious agents, diagnostic tests contribute to the detection and tracking of disease outbreaks. This information helps public health authorities implement timely interventions, such as contact tracing, isolation measures, and targeted vaccination campaigns, to control the spread of infections.

Research and Development: Infectious disease diagnostics drive research and development efforts to improve existing diagnostic methods and develop new technologies. Ongoing advancements in diagnostics contribute to the discovery of novel biomarkers, the enhancement of diagnostic accuracy and sensitivity, and the integration of innovative approaches such as molecular techniques, biosensors, and artificial intelligence.

Market Segmentation:

Segmentation 1: by Application
•    Laboratory Testing
•    Point-of-Care Testing

Laboratory Testing to Dominate the India Emerging Infectious Disease Diagnostics Market (by Application)

Based on application, the laboratory testing segment dominated the India emerging infectious disease diagnostics market in FY2022. Laboratory testing plays a crucial role in the diagnosis and management of infectious diseases. It involves the analysis of patient samples, such as blood, urine, sputum, or tissue, to detect the presence of infectious agents. Microbiological culture is a common technique that involves incubating patient samples on specific growth media to isolate and identify bacteria, fungi, or parasites, which can then be visualized through microscopy.

Segmentation 2: by Technology
•    Polymerase Chain Reaction (PCR)
•    Isothermal Nucleic Acid Amplification Technology (INAAT)
•    Next-Generation Sequencing (NGS)
•    Immunodiagnostics
•    Other Technologies

PCR to Dominate the India Emerging Infectious Disease Diagnostics Market (by Technology)

Based on technology, the India emerging infectious disease diagnostics market was dominated by the PCR segment in FY2022. Nowadays, PCR is usually used in several laboratories around the world, as it amplifies DNA further, allowing the analysis of even small amounts of nucleic acid. With growing technological advancements in molecular biology techniques, PCR has been utilized in several fields, including disease diagnosis, DNA profiling, precision medicine, and gene expression.

Next-generation sequencing (NGS) has revolutionized infectious disease diagnosis by enabling comprehensive and high-throughput analysis of pathogen genomes. Whole genome sequencing (WGS) allows the sequencing of entire pathogen genomes, providing detailed information about genetic variations, antimicrobial resistance genes, and virulence factors. It can identify and characterize pathogens, track outbreaks, and analyze their evolutionary patterns.

Other emerging technologies anticipated to register significant growth include technologies such as digital PCR, INAAT, and clustered regularly interspaced short palindromic repeats (CRISPR).
•    Digital PCR is an advanced molecular diagnostic technique used for infectious disease diagnostics. It enables the absolute quantification of target nucleic acids by partitioning the PCR reaction into thousands of individual reactions.
•    INAAT has emerged as a valuable tool for infectious disease diagnostics. INAAT includes technologies such as loop-mediated isothermal amplification (LAMP) and recombinase polymerase amplification (RPA), which enable rapid and sensitive detection of pathogens without the need for complex equipment or multiple temperature cycles.
•    CRISPR is a relatively new technology, and while it has been leveraged for gene editing and therapeutic purposes ever since the invention of CRISPR/Cas9 gene editing in 2011, it was only in 2016 that CRISPR-Cas systems were first developed to identify nucleic acids for molecular diagnostics.

Segmentation 3: by Type of Infection
•    Bacterial
•    Viral
•    Fungal
•    Other Infections (Parasitic etc)

Bacterial and Viral Segments to Dominate the India Emerging Infectious Disease Diagnostics Market (by Type of Infection)

Based on type of infection, bacterial infectious disease diagnosis involves various methods and techniques to identify the presence of bacterial pathogens in clinical samples. Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.

Viruses have the ability to mutate and, therefore, can lead to the re-emergence of diseases even after one form of the virus has been eradicated or managed. Molecular diagnostic companies are therefore focused on developing tests that can detect a wide range of viruses. Some of the common infections caused by viruses include influenza, genital herpes, COVID-19, hepatitis, mumps, rubella, gastroenteritis, Zika disease, and ebola disease, among others.

Segmentation 4: by Disease Type
•    Respiratory Infections
•    Gastrointestinal Infections
•    Sexually Transmitted Infections (STIs)
•    Neurological Infections
•    Post-Transplant Infections
•    Other Infections

Respiratory Infections to Dominate the India Emerging Infectious Disease Diagnostics Market (by Disease Type)

A vast majority of molecular diagnostic companies offer tests for various kinds of bacteria and viruses responsible for causing respiratory infections. Moreover, the COVID-19 pandemic led to the development of a wide range of tests employing conventional technologies such as reverse transcriptase PCR (RT-PCR) and even leveraging emerging technologies such as RT-LAMP and CRISPR. Several companies now offer multiplex assays that test for influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2 virus.

Segmentation 5: by End User
•    Hospitals and Clinics
•    Diagnostic Laboratories
•    Other End Users

Hospitals and Clinics and Diagnostic Laboratories to Dominate the India Emerging Infectious Disease Diagnostics Market (by End User)

Based on end users, the hospitals and clinics and diagnostic laboratories segments accounted for the largest share of the India emerging infectious disease diagnostics market in FY2022. Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing. In addition to point-of-care testing (POCT), which provides immediate results for rapid diagnosis and management, hospitals and clinics may also rely on laboratory testing for comprehensive analysis. Some healthcare facilities have on-site laboratories equipped with state-of-the-art diagnostic technologies, while others collaborate with external diagnostic laboratories for specialized testing. These laboratory facilities employ various methods, including molecular techniques such as PCR and sequencing, serological assays, and culture-based methods to identify and characterize infectious agents accurately.

Recent Developments in the India Emerging Infectious Disease Diagnostics Market

•    In February 2023, Thermo Fisher Scientific Inc. and Mylab announced a pact on test kits for infectious diseases.
•    In February 2023, Biotech startup CrisprBits raised $250,000 in a pre-seed funding round to support the development and commercialization of its CRISPR-based tests.
•    In February 2023, the Food and Drug Administration (FDA) authorized the Xpert Mpox test by Cepheid (parent: DANAHER CORPORATION) for emergency use.
•    In August 2022, Bio-Rad Laboratories, Inc. acquired Curiosity Diagnostics to gain access to PCR ONE, a technology being developed by Curiosity Diagnostics, which can quickly detect a broad range of pathogens.
•    In June 2021, Hologic, Inc. completed the acquisition of Mobidiag to expand its capabilities in molecular diagnostics.
•    In January 2023, CrisprBits developed India’s first CRISPR-based SARS-CoV-2 test with Omicron detection.
•    In March 2023, an India-based startup, Mylab Discovery Solutions Pvt. Ltd., entered into a joint venture with AstraGene LLC, the U.A.E.’s first molecular diagnostics manufacturing company to develop molecular diagnostics in the U.A.E. and Kuwait.
•    In November 2022, Bio-Rad Laboratories, Inc. and NuProbe entered into an exclusive licensing agreement for digital PCR applications.

Demand – Drivers, Restraints, and Opportunities

Market Drivers:

Rising Incidence of Emerging Infectious Diseases in India: The incidence of emerging infectious diseases in India has witnessed a steady rise in recent years, contributing significantly to the expansion of the country’s emerging infectious disease diagnostics market. India emerging infectious disease diagnostics market has experienced substantial growth due to multiple factors. In addition to increased awareness and government initiatives, the country’s past encounters with outbreaks such as Zika, Nipah, and the COVID-19 pandemic have underscored the critical importance of preparedness. As a result, hospitals, laboratories, and healthcare institutions have been channeling resources into advanced diagnostic technologies to detect emerging infectious diseases swiftly and accurately.

Market Restraints:

Inadequate Healthcare Infrastructure and Facilities: The India emerging infectious disease diagnostics market faces significant constraints due to inadequate healthcare infrastructure and facilities. These challenges could have a substantial impact on the ability to effectively diagnose and manage infectious diseases in the country.

For instance, the presence of limited healthcare infrastructure in many parts of India, particularly in rural and remote areas, poses a significant hurdle. These regions often lack well-equipped laboratories and diagnostic facilities, making it difficult to conduct timely and accurate diagnostic tests. As a result, individuals in these underserved areas may not have access to the diagnostics they need, which can lead to delayed diagnoses and increased disease transmission.

Market Opportunities:

Development of Technologically Advanced Platforms in India for Diagnosis: The development of technologically advanced diagnostic platforms in India represents a significant opportunity for players in the emerging infectious disease diagnostics market. The development of advanced diagnostic platforms can help address some of the existing constraints in the healthcare system, such as inadequate healthcare infrastructure and limited access to diagnostics in rural and remote areas.
These advancements include the development of molecular diagnostics, point-of-care testing, immunoassays, and automated systems, among others. These advancements also provide rapid and accurate results, enabling healthcare professionals to make timely treatment decisions.

How can this report add value to an organization?

Workflow/Innovation Strategy: The India emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: In the India emerging infectious disease diagnostics market product launches, upgradations, and approvals accounted for the maximum number of key developments, i.e., over 75.89% of the total developments in the India emerging infectious disease diagnostics market, as of September 2023.

Competitive Strategy: The India emerging infectious disease diagnostics market is fragmented with several established as well as emerging players. Key players in the India emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

•    The base year considered for the calculation of the market size is 2022. The historical year analysis has been done from FY2020 to FY2021, and the market size has been calculated for FY2022 and projected for the period 2023-2033.
•    The geographical distribution of the market revenue is estimated to be the same as the company’s net revenue distribution. All the numbers are adjusted off to two digits after decimal for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. CAGR is calculated from 2023 to 2033.
•    The market has been mapped based on different types of products available in the market and based on several indications. All the key companies that have a significant number of offerings to the India emerging infectious disease diagnostics market have been considered and profiled in the report.
•    In the study, the primary respondent’s verification has been considered to finalize the estimated market for the India emerging infectious disease diagnostics market.
•    The latest annual reports of each market player have been taken into consideration for market revenue calculation.
•    Market strategies and developments of key players have been considered for the calculation of sub-segment split.
•    The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website or from the annual reports of the respective company if stated.

Primary Research

The key data points taken from the primary sources include:

•    Validation and triangulation of all the numbers and graphs
•    Validation of the report’s segmentation and key qualitative findings
•    Understanding of the numbers of the various markets for market type

Secondary Research

Open Sources

•    National Center for Biotechnology Information (NCBI), PubMed, Science Direct, World Bank Group, Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), Global Burden Disease (GBD), World Health Organization (WHO), and Indian Council of Medical Research (ICMR)
•    Annual reports, SEC filings, and investor presentations of the leading market players
•    Company websites and detailed study of their portfolio
•    Gold standard magazines, journals, whitepapers, press releases, and news articles
•    Databases

The key data points taken from the secondary sources include:

•    Segmentations, split-ups, and percentage shares
•    Data for market value
•    Key industry trends of the top players in the market
•    Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
•    Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

Infectious disease diagnostics encompass a range of methods and techniques used to identify and detect infectious agents in individuals suspected of having an infection. These diagnostics play a vital role in timely diagnosis and accuracy, enabling appropriate treatment decisions and public health interventions.

There are two major approaches in the field; one is microbiological culture, which is a fundamental approach in which patient specimens are cultured on specialized growth media to isolate and identify specific pathogens. This technique allows for the determination of the causative organism and the assessment of its antimicrobial susceptibility. Molecular diagnostics, another important approach, utilizes techniques such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) to detect the genetic material of the infectious agent. This enables highly sensitive and specific identification of pathogens, even at low concentrations.

Some of the prominent companies in this market are:

•    Abbott Laboratories
•    Becton, Dickinson and Company
•    bioMérieux S.A.
•    Bio-Rad Laboratories, Inc.
•    Co-Diagnostics, Inc.
•    DANAHER CORPORATION
•    DiaSorin S.p.A.
•    F. Hoffmann-La Roche Ltd
•    Hologic, Inc.
•    QIAGEN N.V.
•    Thermo Fisher Scientific Inc.
•    Siemens Healthineers AG

Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).

The post India Emerging Infectious Disease Diagnostics Market: Focus on Epidemiology, Application, Technology, Type of Infection, Disease Type, and End User – Analysis and Forecast, 2023-2033 first appeared on CRI Report.

The global single-cell multi-omics market is projected to reach $7.72 billion by 2033 from $1.43 billion in 2022, growing at a CAGR of 17.27% during the forecast period 2023-2033.

The market is driven by factors such as a rise in the number of large-scale genomics studies leveraging single-cell RNA sequencing (Sc-RNA), use of the single-cell multi-omics approach for screening and diagnostics of diseases leading to a shift toward personalized medicine, and the increasing use of single-cell multi-omics for drug development.

Market Lifecycle Stage

The global single-cell multi-omics market is developing. The global single-cell multi-omics market has witnessed several collaborations among the market players. The collaborations are aimed at combining capabilities, expanding the customer base, and marketing, among others.

The opportunity for growth of the global single-cell multi-omics market lies in expansion into new research applications, such as single-cell metabolomics.

Impact of COVID-19

The COVID-19 pandemic has significantly impacted the world’s healthcare sector, especially the single-cell multi-omics sector. The pandemic has caused changes in research priorities, supply chain interruptions, and regulatory process modifications that may have had an impact on the operations and activities of single-cell multi-omics.

The future impact of COVID-19 on the demand and supply across the global single-cell multi-omics market depends on the abilities of stakeholders to withstand unforeseeable scenarios in the future. The intensity of impact due to COVID-19 in the future will depend on the current efforts being made by companies to equip their supply chains with the necessary components and processes to remain responsive.

Market Segmentation:

Segmentation 1: by Sample Type

• Animal Sample
• Human Sample
• Microbial Sample

The global single-cell multi-omics market (by sample type) is expected to be dominated by the human sample segment.

Segmentation 2: by Techniques

• Single-Cell Isolation and Dispensing
• Single-Cell Analysis

The global single-cell multi-omics market (by techniques) is expected to be dominated by single-cell isolation and dispensing.

Segmentation 3: By Omics Type

• Single-Cell Transcriptomics
• Single-Cell Genomics
• Single-Cell Proteomics

The global single-cell multi-omics market (by omics type) is expected to be dominated by single-cell transcriptomics.

Segmentation 4: By Product Type

• Kits and Consumables
• Instruments
• Software

The global single-cell multi-omics market (by product type) is expected to be dominated by kits and consumables.

Segmentation 5: By Applications

• Clinical Research
• Translational Research
• Synthetic Biology

The global single-cell multi-omics market (by application) is expected to be dominated by clinical research.

Segmentation 6: By End User

• Biopharmaceutical and Biotech Companies
• Academic and Research Institutions
• Contract Research Organizations (CROs)

The global single-cell multi-omics market (by end user) is expected to be dominated by academic and research institutions.

Segmentation 7: by Region

• North America – U.S., Canada
• Europe – Germany, U.K., France, Italy, Spain, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, Australia, Singapore, and Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World

The global single-cell multi-omics market (by region) is dominated by the North America region.

Recent Developments in Global Single-Cell Multi-Omics Market

• In February 2023, Singleron Biotechnologies and Macrogen Europe announced a strategic alliance to deliver outstanding single-cell multi-omics sequencing solutions, and they combined their strengths.
• In February 2023, Becton, Dickinson and Company announced a new instrument for single-cell multi-omics analysis that would enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines, including immunology, genetic disease research, and cancer and chronic disease research.
• In December 2022, 10x Genomics, Inc. announced the first commercial shipments of its Xenium platform for in situ analysis. Xenium is the next generation of targeted spatial profiling of genes and proteins at subcellular resolution.
• In March 2023, Mission Bio partnered with the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT), leveraging its Tapestri Platform to improve analytical assays and cell manufacturing processes.
• In December 2022, Mission Bio partnered with Abiosciences to co-develop bioinformatics packages for translational and clinical research applications in hematological cancers in China. The goal is to combine Mission Bio’s single-cell DNA and multi-omics capabilities with Abiosciences’ artificial intelligence technology to uncover new disease signatures and address therapeutic resistance.

Demand – Drivers and Limitations

The following are the drivers for the global single-cell multi-omics market:

• Rising Number of Large-Scale Genomics Studies Leveraging Single-Cell RNA Sequencing (Sc-RNA)
• Use of Single-Cell Multi-Omics Approach for Screening and Diagnostics of Diseases Leading to Shift Toward Personalized Medicine
• Increasing Use of Single-Cell Multi-Omics for Drug Development
• Collaborations among Technology Providers and Life Sciences Companies for Accelerating the Research in Single-Cell Multi-Omics

The market is expected to face some limitations as well due to the following challenges:

• High Cost of Single-Cell Analysis and Sequencing
• Limited Availability of Large Online Data Storage and Analysis Platforms

How can this report add value to an organization?

Growth/Marketing Strategy: The global single-cell multi-omics market has seen major development by key players operating in the market, such as new offerings, partnerships, collaboration, and joint ventures.

Competitive Strategy: The global single-cell multi-omics market has witnessed growth in recent years; as the field of single-cell multi-omics grows, it has witnessed increased collaboration between researchers, academic institutions, and industry partners to drive innovation and commercialization of these technologies. Single-cell multi-omics technologies are already being used in a variety of applications, such as cancer research, immunology, and neuroscience. As the technologies continue to improve, they may be applied to other areas of research, such as developmental biology and stem cell research.

Key Companies Profiled

• 10x Genomics, Inc.
• Becton, Dickinson and Company
• BICO GROUP AB (PUBL)
• Bio-Rad Laboratories, Inc.
• BGI Group
• Illumina Inc.
• Fluidigm Corporation
• Menarini Group
• Mission Bio
• Nanostring Technologies, Inc.
• Namocell, Inc.
• PhenomeX,inc.
• QIAGEN NV
• Rarecells Diagnostics
• Scipio Bioscience
• Shilps Sciences
• Singleron Biotechnologies
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• Universal Sequencing Technology Corporation”

The post Single-Cell Multi-Omics Market – A Global and Regional Analysis: Focus on Product Type, Sample Type, Technique, Application, Omics Type, End User, and Country Analysis – Analysis and Forecast, 2023-2033 first appeared on CRI Report.

The global constrained peptide drugs market revenue has been forecasted from 2024 to 2040, following the earliest launch of the first constrained peptide drug in the market.

The market size is anticipated to be $0.06 billion in 2024 and is expected to reach $17.38 billion in 2040, growing at a CAGR of 38.94% during the forecast period 2025-2040.

Market Lifecycle Stage

The global constrained peptide drugs market is anticipated to witness tremendous growth during the forecast period 2025-2040, largely fuelled by the promise of a novel breakthrough constrained peptide pipeline, which is no longer restricted to receptor targets. Advancements in chemical technologies, the therapeutics’ success of commercialized synthetic peptides in recent years, and the affordable pricing being realized by these biomolecules in a wide range of diseases are some additional factors attributing to the projected growth in the forecast period.

Impact

The impact analysis for the factors that significantly affect the market, namely, drivers, restraints, and opportunities, has been provided on a short-term and long-term basis. The short-term assessment considers the period between 2020 and 2025, and the long-term assessment considers the period between 2026 and 2040. Key developments and strategies that have been undertaken by some of the key players in this market have been accounted for evaluation of the impact analysis. Further, these key developments have been assessed to understand the future scope of integrating advancing technologies to enable superior outcomes. Additionally, approvals and launches from companies and patent bodies have also been considered while evaluating the dynamics of the global constrained peptide drugs market.

Impact of COVID-19

In December 2019, Wuhan, a city in the Hubei region of China, was the site of the first detection of the COVID-19 outbreak. Following the classification of COVID-19 as novel pneumonia due to a cluster of unexplained pneumonia cases, efforts to pinpoint the culprit causing the outbreak and outline its genomic sequence got underway right once. The virus has already spread to every country on the globe, and researchers, governments, and business leaders are working to find answers to the crisis at a scale and speed that has never been seen. Testing for SARS-CoV-2 in the populace is one of the main steps that has been put into place globally, among many other measures used to stop the spread of the disease.

The global constrained peptide drugs market is a research-oriented market, having a majority of products in clinical trial stages. It primarily consists of clinical-stage biopharmaceutical companies and global biopharmaceutical companies such as Bicycle Therapeutics PLC, Protagonist Therapeutics, Inc., Aileron Therapeutics, Inc., Polyphor, and Santhera Pharmaceuticals Holding. Since most of the products are in the clinical phase of drug development, constrained peptide drug companies had a low impact on the COVID-19 pandemic.

Although clinical trials were brought to pause because of the lockdowns imposed by governments across the world, causing a delay in the clinical trial timeline, and volunteers and patients were also not able to participate in the clinical trials due to the lockdown; however, few companies took the opportunity of the pandemic and initiated the development of potential drugs against COVID-19. For instance, UCB Pharma participated in the COVID-19 Moonshot, an initiative to expedite the development of an anti-viral for COVID-19. The company’s Phase III investigational molecule Zilucoplan is being studied for acute respiratory distress syndrome associated with COVID-19. Another company, Polyphor Limited, is evaluating Balixafortide, a constrained peptide drug, against COVID-19 as it demonstrated strong efficacy in in-vitro models.

During the pre-COVID-19 period, the global constrained peptide drugs market observed 38 significant key developments. Out of the 38 key developments, the majority were funding activities, primarily focused on the development of novel antibiotics and support clinical trials of certain drugs in clinical phases. For example, in May 2019, Innosuisse awarded Polyphor Ltd. and the University of Zurich to escalate the development of novel antibiotics for treating infections caused by gram-negative bacteria. Furthermore, seven synergistic activities were undertaken in the global constrained peptide drugs market before COVID-19.

Market Segmentation:

Segmentation 1: by Peptide Type

• Disulfide-Rich Peptides (DRPs)
• Cyclic Peptides

Based on peptide type, the disulfide-rich peptides (DRPs) segment is anticipated to dominate the global constrained peptide drugs market in 2040 as the segment includes the pipeline-constrained peptide with either limited existing treatment options or no approved drugs for the disease.

Segmentation 2: by Region

• North America
• Europe
• Asia-Pacific

The North America region is anticipated to dominate the global constrained peptide drugs market (by region) during the forecast period 2025-2040. The reasons contributing to the high demand for constrained peptide drugs in North America are the increasing prevalence of target indications and the early launch of pipeline products in the U.S. and Canada.

Segmentation 3: by Potential Product

• BT5528
• Rusfertide (PTG-300)
• PN-943
• PN-235
• Zilucoplan (RA101495)

Segmentation 4: by Company

• Aileron Therapeutics, Inc.
• Bicycle Therapeutics plc
• Spexis AG
• Protagonist Therapeutics Inc.
• Santhera Pharmaceuticals
• Union Chimique Belge S.A. (UCB)
• Creative Peptides
• Biosynth (Pepscan)
• Pepticom Ltd.
• PeptiDream, Inc.
• Bio-Synthesis Inc
• CPC Scientific Inc.
• Circle Pharma
• Zealand Pharma
• Chugai Pharmaceutical Co., Ltd.

Based on the company, the global constrained peptide drugs market is dominated by 15 major companies.

Recent Developments in the Global Constrained Peptide Drugs Market

• In August 2021, Protagonist Therapeutics Inc. declared the resolution of its collaboration agreement with Zealand Pharma through the reduction of future milestone payments, sales milestones, and royalties owed to Zealand Pharma regarding Protagonist Therapeutics Inc.’s product candidate rusfertide under the terms of the 2012 collaboration agreement between the companies.
• In April 2021, Union Chimique Belge S.A. (UCB) anticipated the release of phase 3 key results for generalized myasthenia gravis (gMG) in the fourth quarter of 2021 and discontinued further development of zilucoplan for immune-mediated necrotizing myopathy (IMNM).
• In September 2021, Polyphor Limited and EnBiotix announced the successful closing of the purchase agreement for EnBiotix to acquire the inhaled antibiotic murepavadin.
• In November 2020, Pepscan Therapeutics B.V. was granted a license for the use of the proprietary CLIPS technology offered by Bicycle Therapeutics plc. The peptide-constraining technology would further help in the development of the company’s products named BT1718 and THR-149.
• In June 2020, Santhera Pharmaceuticals secured a financing commitment of up to $22.1 million from a fund managed by Highbridge Capital Management.

Demand – Drivers and Limitations

The following are the demand drivers for the global constrained peptide drugs market:

• Enhanced Binding Affinity and Cellular Uptake
• Development of Synthetic Constraining Method
• Limitations with Conventional Peptides
• Increasing Government and Private Funding

The market is expected to face some limitations due to the following challenges:

• Increased Competition from Biologics
• Risk of Immunogenic Effects and Unsatisfactory ADME Properties

How can this report add value to an organization?

Workflow/Innovation Strategy: The global constrained peptide drugs market has been segmented (by product) into five candidates, i.e., BT5528, Rusfertide (PTG-300), Zilucoplan (RA101495), PN-235, and PN-943. Over the past decade, peptide drug discovery and development has witnessed a renaissance and scientific thrust as the industry has come to acknowledge the capability of peptide therapeutics in addressing unmet medical needs and the potential of this class of molecules to become a significant accompaniment or even favored alternative treatment to biologics and small molecules.

Peptide therapeutics have demonstrated a novel and selective yet safe mode of action for a wide range of indications. The existing and future development of constrained peptide drugs will continue to burgeon upon the strengths of constrained peptides and innovative technologies employed in the discovery and development, including peptide drug conjugates, multifunctional peptides, and cell-penetrating peptides. Furthermore, limitations associated with presently available peptides have resulted in an urgent need for new design, administration, and synthesis in peptide therapeutics, thereby leading to advancements in the development of constrained peptides.

Growth/Marketing Strategy: Constrained peptides provide noteworthy advantages over linear peptides. An increase in interest in the field of constrained peptides due to the properties they offer led to advancements in peptide synthesis technologies. Companies such as PeptiDream Inc., Pepticom Ltd., Bicycle Therapeutics plc, and Polyphor Limited offer proprietary drug development and constrained peptide synthesis technologies. PeptiDream Inc.’s proprietary Peptide Discovery Platform System (PDPS) technology is used to synthesize synthetic non-native peptide libraries expeditiously, which helps in identifying peptides that can be used as potential drugs for a disease.

Competitive Strategy: Key players in the global constrained peptide drugs market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global constrained peptide drugs market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

The post Constrained Peptide Drugs Market – A Global and Regional Analysis: Focus on Peptide Type, Product, and Region-Wise Analysis – Analysis and Forecast, 2024-2040 first appeared on CRI Report.

Market Overview

The India wastewater treatment market is projected to witness significant growth during the review period, exhibiting a CAGR of 8.50%. The market is expected to reach a value of USD 3,563.06 million by the end of the forecast period (2022-2030).
The India solid waste management market is projected to witness significant growth during the review period, exhibiting a CAGR of 6.84%. The is expected to reach a value of USD 12,691.25 million by the end of the forecast period (2022-2030).
The India air treatment market is projected to witness significant growth during the review period, exhibiting a CAGR of 6.20%. The market is expected to reach a value of USD 10,159.87 million by the end of the forecast period (2022-2030).

Market Segmentation

India wastewater treatment market is segmented by type, chemical, equipment, end-use industry, and region. By type, it is divided into Hazardous and Non-Hazardous.
Based on chemicals, the India wastewater treatment market is divided into pH conditioners, coagulants & flocculants, disinfectant & biocidal products, scale & corrosion inhibitors, anti-foam chemicals, and others.
Based on equipment, India wastewater treatment market is divided into biological, filtration, sludge treatment, disinfection, demineralization, and others.
Based on the end-use industry India wastewater treatment market is divided into the paper & pulp industry, pharma industry, steel industry, food & beverage, petrochemical industry, microelectronics industry, chemical, and others.
India solid waste management market is segmented by type, service, end-use industry, and region. By type, it is divided into Hazardous and Non-Hazardous.
Based on service, India solid waste management market is divided into the collection, incineration, recycling, and others. From which collection segments are poised to account for a vital chunk of the India solid waste management market.
Based on the end-use industry India solid waste management market is divided into the paper & pulp industry, pharma industry, steel industry, food & beverage, petrochemical industry, microelectronics industry, chemical, and others.
India air treatment market is segmented by type, technology, end-use industry, and region. By type, it is divided into Hazardous and Non-Hazardous.
Based on technology, the India air treatment market is divided into wet scrubbers, flue gas desulfurization, catalytic converters, thermal oxidizers, electrostatic precipitators, biogas treatment, and others.
Based on the end-use industry India air treatment market is divided into the paper & pulp industry, pharma industry, steel industry, food & beverage, petrochemical industry, power, microelectronics industry, chemical, and others.

Major Players

Tatva Global Environment Ltd., A2Z Green Waste Management Limited, Xylem Inc., Thermax Limited, Antony Waste Handling Cell Ltd., Synergy Waste Management Pvt. Ltd., Attero, EcoWise, Saahas Zero Waste, NIPRA, Greenobin Recycling Pvt. Ltd., Craste, Lucro, Sampurn(e)arth Environment Solutions Pvt. Ltd. and several local players.

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 14
1.1 INDIA WASTEWATER TREATMENT MARKET 17
1.1.1 INDIA WASTEWATER TREATMENT MARKET, BY TYPE 17
1.1.2 INDIA WASTEWATER TREATMENT MARKET, BY CHEMICAL 18
1.1.3 INDIA WASTEWATER TREATMENT MARKET, BY EQUIPMENT 19
1.1.4 INDIA WASTEWATER TREATMENT MARKET, BY END-USE INDUSTRY 20
1.1.5 INDIA WASTEWATER TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY REGION 21
1.2 INDIA SOLID WASTE MANAGEMENT MARKET 22
1.2.1 INDIA SOLID WASTE MANAGEMENT MARKET, BY TYPE 22
1.2.2 INDIA SOLID WASTE MANAGEMENT MARKET, BY SERVICE 23
1.2.3 INDIA SOLID WASTE MANAGEMENT MARKET, BY END-USE INDUSTRY 24
1.2.4 INDIA SOLID WASTE MANAGEMENT MARKET ATTRACTIVENESS ANALYSIS, BY REGION 25
1.3 INDIA AIR TREATMENT MARKET 26
1.3.1 INDIA AIR TREATMENT MARKET, BY TYPE 26
1.3.2 INDIA AIR TREATMENT MARKET, BY TECHNOLOGY 27
1.3.3 INDIA AIR TREATMENT MARKET, BY END-USE INDUSTRY 28
1.3.4 INDIA AIR TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY REGION 29
2 MARKET INTRODUCTION 30
2.1 DEFINITION 30
2.2 SCOPE OF THE STUDY 30
2.3 MARKET STRUCTURE 31
3 RESEARCH METHODOLOGY 33
3.1 RESEARCH PROCESS 33
3.2 PRIMARY RESEARCH 34
3.3 SECONDARY RESEARCH 35
3.4 MARKET SIZE ESTIMATION 35
3.5 TOP-DOWN AND BOTTOM-UP APPROACH 36
3.6 FORECAST MODEL 37
3.7 LIST OF ASSUMPTIONS & LIMITATIONS 38
4 MARKET DYNAMICS 39
4.1 INTRODUCTION 39
4.2 DRIVERS 40
4.2.1 WASTE TREATMENT AND MANAGEMENT OF THE PHARMA INDUSTRY 40
4.2.2 WASTE TREATMENT AND MANAGEMENT OF THE STEEL INDUSTRY 42
4.2.3 WASTE TREATMENT AND MANAGEMENT OF THE FOOD & BEVERAGE INDUSTRY 43
4.2.4 WASTE TREATMENT AND MANAGEMENT OF THE PETROCHEMICAL INDUSTRY 45
4.2.5 WASTE TREATMENT AND MANAGEMENT OF THE MICROELECTRONICS INDUSTRY 47
4.2.6 WASTE TREATMENT AND MANAGEMENT OF THE CHEMICAL INDUSTRY 48
4.3 RESTRAINTS 49
4.3.1 LACK OF NECESSARY FRAMEWORK FOR COLLECTION AND SEGREGATION OF WASTE 49
4.4 OPPORTUNITIES 50
4.4.1 INNOVATIVE TECHNOLOGIES FOR WATER AND WASTEWATER TREATMENT IN INDIA 50
4.5 TRENDS 51
4.5.1 LATEST WATER TREATMENT TECHNIQUES IN INDIA 51
4.5.2 EPC (ENGINEERING, PROCUREMENT, AND CONSTRUCTION) MODELS ADOPTED BY THE GOVERNMENT 52
5 PORTER’S FIVE FORCES MODEL 54
5.1.1 THREAT OF NEW ENTRANTS 54
5.1.2 BARGAINING POWER OF SUPPLIERS 55
5.1.3 THREAT OF SUBSTITUTES 55
5.1.4 BARGAINING POWER OF BUYERS 55
5.1.5 INTENSITY OF RIVALRY 55
5.2 IMPACT OF COVID 19 INDIA WASTE TREATMENT & MANAGEMENT MARKET 56
5.2.1 IMPACT ON THE SUPPLY CHAIN OF THE INDIA WASTE TREATMENT & MANAGEMENT MARKET 56
5.2.2 IMPACT ON DEMAND FROM END-USE INDUSTRIES 56
6 INDIA WASTEWATER TREATMENT MARKET 58
6.1 INDIA WASTEWATER TREATMENT MARKET (QUALITATIVE ANALYSIS) 58
6.1.1 INDIA WASTEWATER TREATMENT MARKET SUPPLY CHAIN ANALYSIS 58
6.1.1.1 WASTE COLLECTION AND TREATMENT 58
6.1.1.2 DISPOSAL 61
6.1.2 INDIA WASTEWATER TREATMENT MARKET, TECHNOLOGY ANALYSIS 62
6.1.3 STRATEGY OVERVIEW 65
6.2 INDIA WASTEWATER TREATMENT MARKET (QUANTITATIVE ANALYSIS) 66
6.2.1 OVERVIEW 66
6.2.1.1 INDIA WASTEWATER TREATMENT MARKET, BY TYPE 66
6.2.1.1.1 HAZARDOUS 66
6.2.1.1.2 NON-HAZARDOUS 66
6.2.1.2 INDIA WASTEWATER TREATMENT MARKET, BY CHEMICALS 66
6.2.1.2.1 PH CONDITIONERS 66
6.2.1.2.2 COAGULANTS & FLOCCULANTS 66
6.2.1.2.3 DISINFECTANT & BIOCIDAL PRODUCTS 67
6.2.1.2.4 SCALE & CORROSION INHIBITORS 67
6.2.1.2.5 ANTI-FOAM CHEMICALS 67
6.2.1.2.6 OTHERS 67
6.2.1.3 INDIA WASTEWATER TREATMENT MARKET, BY EQUIPMENT 68
6.2.1.3.1 BIOLOGICAL 68
6.2.1.3.2 FILTRATION 68
6.2.1.3.3 SLUDGE TREATMENT 68
6.2.1.3.4 DISINFECTION 68
6.2.1.3.5 DEMINERALIZATION 68
6.2.1.3.6 OTHERS 68
6.2.1.4 INDIA WASTEWATER TREATMENT MARKET, BY END-USE INDUSTRY 69
6.2.1.4.1 PULP & PAPER INDUSTRY 69
6.2.1.4.2 PHARMA INDUSTRY 69
6.2.1.4.3 STEEL INDUSTRY 69
6.2.1.4.4 FOOD & BEVERAGE (INCL. SUGAR INDUSTRY) 69
6.2.1.4.5 PETROCHEMICAL INDUSTRY 69
6.2.1.4.6 MICROELECTRONICS INDUSTRY 69
6.2.1.4.7 CHEMICALS 70
6.2.1.4.8 OTHERS 70
6.2.2 INDIA WASTEWATER TREATMENT MARKET, BY TYPE 71
6.2.3 INDIA WASTEWATER TREATMENT MARKET, BY CHEMICALS 72
6.2.4 INDIA WASTEWATER TREATMENT MARKET, BY EQUIPMENT 2019-2030 73
6.2.5 INDIA WASTEWATER TREATMENT MARKET, BY END-USE INDUSTRY 74
6.2.6 INDIA WASTEWATER TREATMENT MARKET, BY REGION 2019-2030 75
7 INDIA SOLID WASTE MANAGEMENT MARKET 76
7.1 INDIA SOLID WASTE MANAGEMENT MARKET (QUALITATIVE ANALYSIS) 76
7.1.1 INDIA SOLID WASTE MANAGEMENT MARKET SUPPLY CHAIN ANALYSIS 77
7.1.1.1 WASTE COLLECTION AND TREATMENT 77
7.1.1.2 DISPOSAL 77
7.1.2 INDIA SOLID WASTE MANAGEMENT MARKET, TECHNOLOGY ANALYSIS 79
7.1.3 STRATEGY OVERVIEW 81
7.2 INDIA SOLID WASTE MANAGEMENT MARKET (QUANTITATIVE ANALYSIS) 82
7.2.1 OVERVIEW 82
7.2.1.1 INDIA SOLID WASTE MANAGEMENT MARKET, BY TYPE 82
7.2.1.1.1 HAZARDOUS 82
7.2.1.1.2 NON-HAZARDOUS 82
7.2.1.2 INDIA SOLID WASTE MANAGEMENT MARKET, BY SERVICE 82
7.2.1.2.1 COLLECTION 82
7.2.1.2.2 INCINERATION 82
7.2.1.2.3 RECYCLING 82
7.2.1.2.4 OTHERS 82
7.2.1.3 INDIA SOLID WASTE MANAGEMENT MARKET, BY END-USE INDUSTRY 83
7.2.1.3.1 PULP & PAPER INDUSTRY 83
7.2.1.3.2 PHARMA INDUSTRY 83
7.2.1.3.3 STEEL INDUSTRY 83
7.2.1.3.4 FOOD & BEVERAGE (INCL. SUGAR INDUSTRY) 83
7.2.1.3.5 PETROCHEMICAL INDUSTRY 83
7.2.1.3.6 MICROELECTRONICS INDUSTRY 84
7.2.1.3.7 CHEMICALS 84
7.2.1.3.8 OTHERS 84
7.2.2 INDIA SOLID WASTE MANAGEMENT MARKET, BY TYPE 85
7.2.3 INDIA SOLID WASTE MANAGEMENT MARKET, BY SERVICE 86
7.2.4 INDIA SOLID WASTE MANAGEMENT: MARKET ESTIMATES & FORECAST BY SERVICE, 2019–2030 86
7.2.5 INDIA SOLID WASTE MANAGEMENT MARKET, BY END-USE INDUSTRY 87
7.2.6 INDIA SOLID WASTE MANAGEMENT: MARKET ESTIMATES & FORECAST BY END-USE INDUSTRY, 2019–2030 87
7.2.7 INDIA SOLID WASTE MANAGEMENT MARKET, BY REGION 88
8 INDIA AIR TREATMENT MARKET 90
8.1 INDIA AIR TREATMENT MARKET (QUALITATIVE ANALYSIS) 90
8.1.1 INDIA AIR TREATMENT MARKET SUPPLY CHAIN ANALYSIS 90
8.1.2 INDIA AIR TREATMENT MARKET, TECHNOLOGY ANALYSIS 90
8.1.3 STRATEGY OVERVIEW 92
8.2 INDIA AIR TREATMENT MARKET (QUANTITATIVE ANALYSIS) 92
8.2.1 OVERVIEW 92
8.2.1.1 INDIA AIR TREATMENT MARKET, BY TYPE 92
8.2.1.1.1 HAZARDOUS 92
8.2.1.1.2 NON-HAZARDOUS 92
8.2.1.2 INDIA AIR TREATMENT MARKET, BY TECHNOLOGY 93
8.2.1.2.1 WET SCRUBBERS 93
8.2.1.2.2 FLUE GAS DESULFURIZATION 93
8.2.1.2.3 THERMAL OXIDIZERS 93
8.2.1.2.4 CATALYTIC CONVERTERS 93
8.2.1.2.5 ELECTROSTATIC PRECIPITATORS 93
8.2.1.2.6 CARBON CAPTURE & STORAGE 93
8.2.1.2.7 BIOGAS TREATMENT 94
8.2.1.2.8 OTHERS 94
8.2.1.3 INDIA AIR TREATMENT MARKET, BY END-USE INDUSTRY 94
8.2.1.3.1 PULP & PAPER INDUSTRY 94
8.2.1.3.2 PHARMA INDUSTRY 95
8.2.1.3.3 STEEL INDUSTRY 95
8.2.1.3.4 FOOD & BEVERAGE 95
8.2.1.3.5 PETROCHEMICAL 95
8.2.1.3.6 POWER 95
8.2.1.3.7 MICROELECTRONICS INDUSTRY 96
8.2.1.3.8 CHEMICALS 96
8.2.1.3.9 OTHERS 96
8.2.2 INDIA AIR TREATMENT MARKET, BY TYPE 2019-2030 97
8.2.3 INDIA AIR TREATMENT MARKET, BY TECHNOLOGY 2019-2030 98
8.2.4 INDIA AIR TREATMENT MARKET, BY END-USE INDUSTRY 2019-2030 99
8.2.5 INDIA AIR TREATMENT MARKET, BY REGION 2019-2030 100
9 COMPETITIVE LANDSCAPE 101
9.1 COMPETITIVE OVERVIEW 101
9.2 GLOBAL RECENT DEVELOPMENTS 101
9.3 INDIA WASTE TREATMENT & MANAGEMENT MARKET SHARE ANALYSIS 103
9.4 MARKET STRATEGY ANALYSIS 104
9.5 COMPETITIVE BENCHMARKING 104
10 COMPANY PROFILES 105
10.1 VEOLIA ENVIRONMENT SA 105
10.1.1 COMPANY OVERVIEW 105
10.1.2 FINANCIAL OVERVIEW 106
10.1.3 PRODUCTS/SERVICES OFFERED 106
10.1.4 KEY DEVELOPMENTS 107
10.1.5 SWOT ANALYSIS 108
10.1.6 KEY STRATEGIES 108
10.2 SUEZ SA 109
10.2.1 COMPANY OVERVIEW 109
10.2.2 FINANCIAL OVERVIEW 110
10.2.3 PRODUCTS/SERVICES OFFERED 110
10.2.4 KEY DEVELOPMENTS 111
10.2.5 SWOT ANALYSIS 111
10.2.6 KEY STRATEGIES 111
10.3 XYLEM INC. 112
10.3.1 COMPANY OVERVIEW 112
10.3.2 FINANCIAL OVERVIEW 113
10.3.3 PRODUCTS/SERVICES OFFERED 113
10.3.4 KEY DEVELOPMENTS 114
10.3.5 SWOT ANALYSIS 115
10.3.6 KEY STRATEGIES 115
10.4 THERMAX LIMITED 116
10.4.1 COMPANY OVERVIEW 116
10.4.2 FINANCIAL OVERVIEW 117
10.4.3 PRODUCTS/SERVICES OFFERED 117
10.4.4 KEY DEVELOPMENTS 118
10.4.5 SWOT ANALYSIS 119
10.4.6 KEY STRATEGIES 119
10.5 DUPONT 120
10.5.1 COMPANY OVERVIEW 120
10.5.2 FINANCIAL OVERVIEW 121
10.5.3 PRODUCTS/SERVICES OFFERED 121
10.5.4 KEY DEVELOPMENTS 122
10.5.5 SWOT ANALYSIS 122
10.5.6 KEY STRATEGIES 122
10.6 3M 123
10.6.1 COMPANY OVERVIEW 123
10.6.2 FINANCIAL OVERVIEW 124
10.6.3 PRODUCTS/SERVICES OFFERED 124
10.6.4 KEY DEVELOPMENTS 125
10.6.5 SWOT ANALYSIS 125
10.6.6 KEY STRATEGIES 125
10.7 KEMIRA 126
10.7.1 COMPANY OVERVIEW 126
10.7.2 FINANCIAL OVERVIEW 127
10.7.3 PRODUCTS/SERVICES OFFERED 127
10.7.4 KEY DEVELOPMENTS 128
10.7.5 SWOT ANALYSIS 128
10.7.6 KEY STRATEGIES 129
10.8 TATVA GLOBAL ENVIRONMENT LTD. 130
10.8.1 COMPANY OVERVIEW 130
10.8.2 FINANCIAL OVERVIEW 131
10.8.3 PRODUCTS/SERVICES OFFERED 131
10.8.4 KEY DEVELOPMENTS 132
10.8.5 SWOT ANALYSIS 132
10.8.6 KEY STRATEGIES 132
10.9 A2Z GREEN WASTE MANAGEMENT LIMITED 133
10.9.1 COMPANY OVERVIEW 133
10.9.2 FINANCIAL OVERVIEW 134
10.9.3 PRODUCTS/SERVICES OFFERED 135
10.9.4 KEY DEVELOPMENTS 135
10.9.5 SWOT ANALYSIS 136
10.9.6 KEY STRATEGIES 136
10.10 BVG INDIA LIMITED 137
10.10.1 COMPANY OVERVIEW 137
10.10.2 FINANCIAL OVERVIEW 138
10.10.3 PRODUCTS/SERVICES OFFERED 138
10.10.4 KEY DEVELOPMENTS 139
10.10.5 SWOT ANALYSIS 139
10.10.6 KEY STRATEGIES 139
11 APPENDIX 140
11.1 REFERENCES 140
11.2 RELATED REPORTS 141
 

The post India Waste Treatment and Management Market Research Report Forecast to 2030 first appeared on CRI Report.

Market Overview

The pharmaceutical isolator market industry is projected to register a healthy CAGR of 9.57% during the forecast period. The rising interest in pharmaceutical isolators across flourishing pharmaceutical and biotechnological areas and developing Research and development Drives in the pharmaceutical business is driving the market development.
As of late, pharmaceutical isolators have seen a vigorous interest because of a great many applications in the pharmaceutical and biotechnological area for creation and control purposes, for example, microbiological tests, cell treatment handling, underway of cutting-edge treatment restorative items (ATMP), and for taking care of and moving of medications.
Besides, the pharmaceutical isolator is progressively critical in the pharmaceutical and biotech industry. It helps with lessening working expenses and upgrading creation run capacity. What’s more, the pharmaceutical isolator occupies less room and may require less upkeep. They additionally have low working costs. In this manner, the rising interest for pharmaceutical isolators across flourishing pharmaceutical and biotechnological areas is projected to support the market development during the estimated time frame.

Market Segmentation

The Pharmaceutical Isolator Market Segmentation, based on type, includes open isolators and closed isolators. By the product type market is divided into sterility test isolator, process isolator, and decontamination pass box.
based on product class the Pharmaceutical Isolator Market is divided into ISO class 3 and ISO class 5. Based on end-user that includes biopharma/cell & gene therapy companies, academic & research institutes, hospitals, and contract research organization & contract manufacturing organization.

Regional Insights

The North American pharmaceutical isolator market is supposed to represent USD 4.61 billion in 2021 and is supposed to display a 7.28% CAGR during the review time frame. This is credited to creating medical care framework, developing interest in pharmaceutical isolators, low functional expense, and the presence of countless

Market Players

in the region.
Europe pharmaceutical isolator market is supposed to represent the second-biggest market share because of the ascent in the interest for pharmaceutical isolators from pharmaceutical and biotechnological ventures, high sterility confirmation, and low functional expenses. Further, the Rest of the Europe pharmaceutical isolator market is held the biggest market share, and the UK pharmaceutical isolator market is supposed to quickest developing market, in the European region.
The Asia-Pacific pharmaceutical isolator market is anticipated to register a CAGR of 9.08% during the study period. This is because of the developing medical services consumption and developing utilization of disinfected strategies.
The Rest of the World incorporates the Middle East, Africa, and Latin America. The developing predominance of constant issues or expanded center around Research and development proficiencies regarding medical devices fundamentally adds to market development. Besides, rising progressions like compactness, network, getting the fixed position, developing spotlight on clinical gadgets disinfection innovation, and rising clinical the travel industry are other significant variables that will additionally increment rewarding market learning experiences in the Center East, Africa, and Latin America.

Major Players

Key Companies in the Pharmaceutical Isolator Market are Skan AG (Switzerland), Azbil Telstar s.l.u (Spain), Cytiva (US), NuAire Inc (US), Schematic Engineering Industries (India), MBraun GMBH (Germany), Fedegari Autoclavi S.p.A(Italy), Hosokawa Micron B.V (Netherlands), Syntegon Technology (Germany), Isotech Design (Canada), and Getinge AB (Sweden).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 RISING DEMAND FOR THE PHARMACEUTICAL ISOLATORS ACROSS BOOMING PHARMACEUTICAL & BIOTECHNOLOGICAL SECTORS

4.2.2 GROWING R&D INITIATIVES IN THE PHARMACEUTICAL INDUSTRY

4.3 RESTRAINTS

4.3.1 COMPLEX AND VARIED PHARMACEUTICAL ISOLATOR REGULATIONS ACROSS COUNTRIES

4.3.2 SHORTAGE OF TRAINED AND EXPERIENCED MEDICAL SPECIALISTS

4.4 OPPORTUNITY

4.4.1 INCREASING ADOPTION OF PHARMACEUTICAL ISOLATORS IN EMERGING ECONOMIES

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY CHAIN ANALYSIS

5.1.1 R&D AND DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION, MARKETING, AND SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 BARGAINING POWER OF SUPPLIERS

5.2.2 BARGAINING POWER OF BUYERS

5.2.3 THREAT OF NEW ENTRANTS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT ANALYSIS OF COVID-19 ON PHARMACEUTICAL ISOLATOR MARKET

5.3.1 OVERVIEW

5.3.2 IMPACT ON SUPPLY CHAIN

5.3.3 IMPACT ON PRODUCTION

5.3.4 IMPACT ON REGIONS

5.3.5 DEMAND SUPPLY GAP ANALYSIS

6 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY TYPE

6.1 OVERVIEW

6.2 OPEN ISOLATOR

6.3 CLOSED ISOLATOR

7 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 STERILITY TEST ISOLATOR

7.3 PROCESS ISOLATOR

7.4 DECONTAMINATION PASS BOX

8 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY PRODUCT CLASS

8.1 OVERVIEW

8.2 ISO CLASS 3

8.3 ISO CLASS 5

9 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 STERILITY TESTING

9.3 SAMPLING/ WEIGHING/ DISTRIBUTION

9.4 ANIMAL LABORATORIES

9.5 ASEPTIC TISSUE HANDLING/MICROBIOLOGY TESTING/PATHOGENIC SAMPLING

9.6 DEFILTRATION AND DRYING

9.7 OTHERS

10 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY END USER

10.1 OVERVIEW

10.2 BIOPHARMA/CELL & GENE THERAPY COMPANIES

10.3 ACADEMIC & RESEARCH INSTITUTES

10.4 HOSPITALS

10.5 CONTRACT RESEARCH ORGANIZATION & CONTRACT MANUFACTURING ORGANIZATION

11 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY REGION

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 US

11.2.2 CANADA

11.3 EUROPE

11.3.1 GERMANY

11.3.2 FRANCE

11.3.3 UK

11.3.4 ITALY

11.3.5 SPAIN

11.3.6 REST OF EUROPE

11.4 ASIA-PACIFIC

11.4.1 JAPAN

11.4.2 CHINA

11.4.3 INDIA

11.4.4 AUSTRALIA

11.4.5 SOUTH KOREA

11.4.6 REST OF ASIA-PACIFIC

11.5 REST OF THE WORLD

11.5.1 MIDDLE EAST

11.5.2 AFRICA

11.5.3 LATIN AMERICA

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW

12.2 COMPETITIVE BENCHMARKING

12.3 MAJOR GROWTH STRATEGY IN THE PHARMACEUTICAL ISOLATOR MARKET

12.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE PHARMACEUTICAL ISOLATOR MARKET

12.5 KEY DEVELOPMENT ANALYSIS

12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

12.6.1 EXPANSION/AGREEMENT

12.6.2 MERGERS & ACQUISITIONS

12.6.3 SALES

13 COMPANY PROFILES

13.1 SKAN AG

13.1.1 COMPANY OVERVIEW

13.1.2 FINANCIAL OVERVIEW

13.1.3 PRODUCTS OFFERED

13.1.4 KEY DEVELOPMENTS

13.1.5 SWOT ANALYSIS

13.1.6 KEY STRATEGIES

13.2 AZBIL TELSTAR S.L.U

13.2.1 COMPANY OVERVIEW

13.2.2 FINANCIAL OVERVIEW

13.2.3 PRODUCTS OFFERED

13.2.4 KEY DEVELOPMENTS

13.2.5 SWOT ANALYSIS

13.2.6 KEY STRATEGIES

13.3 CYTIVA

13.3.1 COMPANY OVERVIEW

13.3.2 FINANCIAL OVERVIEW

13.3.3 PRODUCTS OFFERED

13.3.4 KEY DEVELOPMENTS

13.3.5 SWOT ANALYSIS

13.3.6 KEY STRATEGIES

13.4 NUAIRE INC.

13.4.1 COMPANY OVERVIEW

13.4.2 FINANCIAL OVERVIEW

13.4.3 PRODUCTS OFFERED

13.4.4 KEY DEVELOPMENTS

13.4.5 SWOT ANALYSIS

13.4.6 KEY STRATEGIES

13.5 SCHEMATIC ENGINEERING INDUSTRIES

13.5.1 COMPANY OVERVIEW

13.5.2 FINANCIAL OVERVIEW

13.5.3 PRODUCTS OFFERED

13.5.4 KEY DEVELOPMENTS

13.5.5 SWOT ANALYSIS

13.5.6 KEY STRATEGIES

13.6 MBRAUN GMBH

13.6.1 COMPANY OVERVIEW

13.6.2 FINANCIAL OVERVIEW

13.6.3 PRODUCTS OFFERED

13.6.4 KEY DEVELOPMENTS

13.6.5 KEY STRATEGIES

13.7 FEDEGARI AUTOCLAVI S.P.A

13.7.1 COMPANY OVERVIEW

13.7.2 FINANCIAL OVERVIEW

13.7.3 PRODUCT OFFERED

13.7.4 KEY DEVELOPMENTS

13.7.5 KEY STRATEGIES

13.8 HOSOKAWA MICRON B.V.

13.8.1 COMPANY OVERVIEW

13.8.2 FINANCIAL OVERVIEW

13.8.3 PRODUCTS OFFERED

13.8.4 KEY DEVELOPMENTS

13.8.5 SWOT ANALYSIS

13.8.6 KEY STRATEGIES

13.9 SYNTEGON TECHNOLOGY

13.9.1 COMPANY OVERVIEW

13.9.2 FINANCIAL OVERVIEW

13.9.3 PRODUCTS OFFERED

13.9.4 KEY DEVELOPMENTS

13.9.5 SWOT ANALYSIS

13.9.6 KEY STRATEGIES

13.10 ISOTECH DESIGN

13.10.1 COMPANY OVERVIEW

13.10.2 FINANCIAL OVERVIEW

13.10.3 PRODUCTS OFFERED

13.10.4 KEY DEVELOPMENTS

13.10.5 KEY STRATEGIES

13.11 GETINGE AB

13.11.1 COMPANY OVERVIEW

13.11.2 FINANCIAL OVERVIEW

13.11.3 PRODUCTS OFFERED

13.11.4 KEY DEVELOPMENTS

13.11.5 KEY STRATEGIES

14 APPENDIX

14.1 REFERENCES

14.2 RELATED REPORTS

The post Pharmaceutical Isolator Market Forecast to 2030 first appeared on CRI Report.

Market Overview

Fill Finish Manufacturing Market is anticipated to register a significant CAGR of 10.82% during the review period. The progression in fill finish manufacturing methods developing Research and development in the drug industry are driving market development.
Utilizing isolators and Limited admittance Barrier Systems (RABS), fill finish activities really confine human administrators from the fill finish process by laying out sterile manufacturing conditions. Barrier seclusion systems, which are coordinated fill finish machines equipped for playing out all phases of fill finish processes, are being created by numerous gear producers in the fill finish manufacturing market. The fill finish process is mind-boggling and inclined to defilement because independent hardware utilized in fill finish tasks, rather than barrier confinement systems, is time-and cash consuming. Numerous biopharmaceutical organizations are executing isolators or RABS in their medication creation offices because of their benefits.
Besides, customary treated steel systems need extra cleaning and cleansing (CIP/SIP) in conventional aseptic fill finish processes, though a solitary-use framework skirts the vital sanitization steps and rates up changeovers by smoothing out finish of-clump breakdown and disinfecting methodology. This is essentially on the grounds that solitary-use systems don’t need costly and tedious disinfection methodology. Furthermore, single-use systems have monetary advantages since they demand less investment to set up and bring down, which brings down work costs. Single-use systems likewise diminish the requirement for synthetic substances and capital consumptions while utilizing less water and energy. The market development is emphatically impacted by the enlivening speed of mechanical progressions in fill finish manufacturing processes.

Market Segmentation

Consumables and tools are included in the product segmentation of the Fill Finish Manufacturing Market. Prefilled syringes, vials, cartridges, and other consumables such as ampoules, bottles, and IV bags are among the consumables segments.
The global fill-finish manufacturing industry’s modality-based segments include recombinant proteins, monoclonal antibodies, vaccines, cell treatments, viral gene therapies, non-viral gene therapies, and other products. Vaccinations are classified as mRNA, DNA, inactivated, viral vector, live-attenuated, and others, including toxoid.
The market is divided into contract manufacturing firms, biotechnology and pharmaceutical firms, and other groups that include academic and research institutions, according to end users.

Regional Insights

The development of the North America fill finish manufacturing market is broad innovative work exercises as well as cutting-edge manufacturing of inventive biopharmaceutical and drug items.
North American fill-finish manufacturing market represents the biggest market share because of broad innovative work exercises, developing ventures by worldwide organizations, and high-level manufacturing of imaginative biopharmaceutical and drug items. Moreover, the US fill-finish manufacturing market held the biggest market offer and the Canadian fill-finish manufacturing market represented the second biggest market in North America.
The Asia-Pacific fill-finish manufacturing Market is supposed to register a fastest growing market by 2030. This is because of expanding speculations by CMOs and key biopharmaceutical players, expanding government support, and advancements in Research and development foundations around here.

Major Players

The

Major Players

operating in the Fill Finish Manufacturing market are Thermo Fisher Scientific Inc. (US), OPTIMA Packaging Group GmbH (Germany), Fujifilm Holdings Corporation (Japan), Curia Global, Inc. (US), Cytiva (US), Baxter (US), Becton, Dickinson, and Company (US), SGD Pharma (France), Aenova Group (Germany), Groninger & co. GmbH (Germany) among others.

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA MINING

3.3 SECONDARY RESEARCH

3.4 PRIMARY RESEARCH

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 ADVANCEMENT IN FILL FINISH MANUFACTURING TECHNIQUES

4.2.2 GROWING R&D IN PHARMACEUTICAL INDUSTRY

4.2.3 DRIVERS IMPACT ANALYSIS

4.3 RESTRAINTS

4.3.1 HIGH COST AND RISK ASSOCIATED WITH THE RABS AND ISOLATORS

4.3.2 RESTAINTS IMPACT ANALYSIS

4.4 OPPORTUNITY

4.4.1 RISE IN DEMAND FOR FILL FINISH MANUFACTURING IN EMERGING MARKET

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D AND DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES SERVICES AND REVIEW

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19

6 GLOBAL FILL FINISH MANUFACTURING MARKET, BY PRODUCT

6.1 OVERVIEW

6.2 CONSUMABLES

6.2.1 PREFILLED SYRINGES

6.2.1.1 GLASS PREFILLED SYRINGES

6.2.2 PLASTIC PREFILLED SYRINGES

6.2.3 VIALS

6.2.3.1 GLASS VIALS

6.2.3.2 PLASTIC VIALS

6.2.4 CARTRIDGES

6.2.5 OTHERS

6.3 INSTRUMENTS

6.3.1 SYSTEM MACHINE

6.3.1.1 INTEGRATED SYSTEMS

6.3.1.2 STANDALONE SYSTEMS

6.3.2 MACHINE PRODUCT

6.3.2.1 AUTOMATED MACHINES

6.3.2.2 SEMI-AUTOMATED & MANUAL MACHINES

7 GLOBAL FILL FINISH MANUFACTURING MARKET, BY MODALITY

7.1 OVERVIEW

7.2 RECOMBINANT PROTEINS

7.3 MONOCLONAL ANTIBODIES

7.4 VACCINES

7.4.1 MRNA

7.4.2 DNA

7.4.3 INACTIVATED

7.4.4 VIRAL VECTOR

7.4.5 LIVE-ATTENUATED

7.4.6 OTHERS

7.5 CELL THERAPIES

7.6 VIRAL GENE THERAPIES

7.7 NON-VIRAL GENE THERAPIES

7.8 OTHERS

8 GLOBAL FILL FINISH MANUFACTURING MARKET, BY END USER

8.1 OVERVIEW

8.2 CONTRACT MANUFACTURING ORGANIZATION

8.3 BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES

8.4 OTHERS

9 GLOBAL FILL FINISH MANUFACTURING MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 UK

9.3.3 FRANCE

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA-PACIFIC

The Growth In The Biopharmaceutical Industries In The Region Is Expected To Grow The Fill Finish Manufacturing Market. Also, The Factors Such As Increasing Investments By CMOs & Key Biopharmaceutical Players, Increasing Government Support, Developments In R&D Infrastructure Are Propelling The Market Growth.

9.4.1 CHINA

9.4.2 JAPAN

9.4.3 INDIA

9.4.4 SOUTH KOREA

9.4.5 AUSTRALIA

9.4.6 REST OF ASIA PACIFIC

9.5 REST OF THE WORLD

The Rest Of The World Is Segmented Into The Middle East, Africa, And Latin America. The Fill Finish Manufacturing Market In The Above-Mentioned Regions Is Likely To Witness Growth Due To Improving Healthcare Facilities, Supportive Government Regulations And Increasing Research Activities In The Region. Furthermore, Global Companies Are Expanding Their R&D Capabilities In The Region Through Subsidiaries, Supplementing The Growth Of The Fill Finish Manufacturing Market.

9.5.1 MIDDLE EAST

9.5.2 AFRICA

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL FILL FINISH MANUFACTURING MARKET

10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL FILL FINISH MANUFACTURING MARKET

10.5 KEY DEVELOPMENT ANALYSIS

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 PRODUCT LAUNCH

10.6.2 MERGER & ACQUISITION

10.6.3 COLLABORATION/ AGREEMENT/ EXPANSION

10.7 FINANCIAL MATRIX

10.7.1 SALES (USD MILLION), 2021

10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021

11 COMPANY PROFILES

11.1 THERMO FISHER SCIENTIFIC INC.

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL ANALYSIS

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 CYTIVA

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 FUJIFILM HOLDINGS CORPORATION

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 OPTIMA PACKAGING GROUP GMBH

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 KEY STRATEGIES

11.5 CURIA GLOBAL, INC.

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 KEY STRATEGIES

11.6 BAXTER

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.6.6 KEY STRATEGIES

11.7 BECTON, DICKINSON AND COMPANY

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 SWOT ANALYSIS

11.7.6 KEY STRATEGIES

11.8 AENOVA GROUP

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 KEY STRATEGIES

11.9 SGD PHARMA

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 KEY STRATEGIES

11.10 GRONINGER & CO. GMBH

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.1.1 RELATED REPORTS

The post Fill Finish Manufacturing Market Forecast to 2030 first appeared on CRI Report.